https://trial.medpath.com/news/diamyd-medical-receives-u-s-fda-fast-track-designation-for-diamyd-r 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-receives-u-s-fda-fast-track-designation-for-diamyd-r 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-publication-highlights-safety-and-potential-benefits-of-redosing 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-publication-highlights-safety-and-potential-benefits-of-redosing 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/results-from-diamyd-r-antigen-specific-immunotherapy-trial-in-lada 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/results-from-diamyd-r-antigen-specific-immunotherapy-trial-in-lada 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-new-publication-highlights-safety-and 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-new-publication-highlights-safety-and 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-receives-positive-feedback-from-fda-on-potential 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-receives-positive-feedback-from-fda-on-potential 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-and-dr-reddy-s-sign-india-distribution-deal-for-qdenga-dengue-vaccine 2026-09-19T00:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-and-dr-reddy-s-sign-india-distribution-deal-for-qdenga-dengue-vaccine 2026-09-19T00:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-amneal-s-lanreotide-injection-as-generic-rival-to-somatuline-depot 2026-09-18T21:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-amneal-s-lanreotide-injection-as-generic-rival-to-somatuline-depot 2026-09-18T21:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/all-50-states-join-medicaid-most-favored-nation-drug-pricing-model 2026-09-18T21:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/all-50-states-join-medicaid-most-favored-nation-drug-pricing-model 2026-09-18T21:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-intrabio-s-aqneursa-levacetylleucine-for-ataxia-telangiectasia-the-first-treatment-anywhere-for-the-disease 2026-09-18T20:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-intrabio-s-aqneursa-levacetylleucine-for-ataxia-telangiectasia-the-first-treatment-anywhere-for-the-disease 2026-09-18T20:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-full-approval-to-lilly-s-inluriyo-plus-verzenio-in-esr1-mutated-advanced-breast-cancer 2026-09-18T19:42:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-full-approval-to-lilly-s-inluriyo-plus-verzenio-in-esr1-mutated-advanced-breast-cancer 2026-09-18T19:42:23+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-enhertu-plus-pertuzumab-and-datroway-as-first-line-metastatic-breast-cancer-regimens 2026-09-18T17:42:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-enhertu-plus-pertuzumab-and-datroway-as-first-line-metastatic-breast-cancer-regimens 2026-09-18T17:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-reports-positive-phase-iii-sanovo-trial-results-in-lung-cancer 2026-09-18T17:42:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hutchmed-reports-positive-phase-iii-sanovo-trial-results-in-lung-cancer 2026-09-18T17:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-cosentyx-for-polymyalgia-rheumatica-setting-up-first-il-17a-approval-in-europe 2026-09-18T16:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-cosentyx-for-polymyalgia-rheumatica-setting-up-first-il-17a-approval-in-europe 2026-09-18T16:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-astrazeneca-s-klygefa-gefurulimab-for-generalised-myasthenia-gravis-in-the-eu 2026-09-18T13:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-astrazeneca-s-klygefa-gefurulimab-for-generalised-myasthenia-gravis-in-the-eu 2026-09-18T13:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/us-weighs-allowing-most-pharma-licensing-deals-with-china 2026-09-18T13:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-weighs-allowing-most-pharma-licensing-deals-with-china 2026-09-18T13:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-senaparib-as-first-line-maintenance-therapy-in-advanced-ovarian-cancer 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-senaparib-as-first-line-maintenance-therapy-in-advanced-ovarian-cancer 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-12-new-medicines-including-first-oral-daily-hidradenitis-suppurativa-option-and-earlier-line-tecvayli 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-12-new-medicines-including-first-oral-daily-hidradenitis-suppurativa-option-and-earlier-line-tecvayli 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-roche-s-ocrevus-for-pediatric-relapsing-ms-citing-48-relapse-reduction 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-roche-s-ocrevus-for-pediatric-relapsing-ms-citing-48-relapse-reduction 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-corcept-s-lifyorli-plus-nab-paclitaxel-for-platinum-resistant-ovarian-cancer 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-corcept-s-lifyorli-plus-nab-paclitaxel-for-platinum-resistant-ovarian-cancer 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/ema-committee-backs-sogroya-for-idiopathic-short-stature-in-children 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-committee-backs-sogroya-for-idiopathic-short-stature-in-children 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/eu-chmp-backs-perioperative-keytruda-plus-padcev-for-resectable-muscle-invasive-bladder-cancer 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-chmp-backs-perioperative-keytruda-plus-padcev-for-resectable-muscle-invasive-bladder-cancer 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-zealand-pharma-s-zeydovio-glepaglutide-for-short-bowel-syndrome 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-zealand-pharma-s-zeydovio-glepaglutide-for-short-bowel-syndrome 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-tecvayli-teclistamab-monotherapy-in-second-line-relapsed-refractory-multiple-myeloma 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-tecvayli-teclistamab-monotherapy-in-second-line-relapsed-refractory-multiple-myeloma 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-enhertu-as-adjuvant-therapy-for-her2-positive-breast-cancer-with-residual-disease 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-enhertu-as-adjuvant-therapy-for-her2-positive-breast-cancer-with-residual-disease 2026-09-18T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-alexion-s-efzimfotase-alfa-bla-for-hypophosphatasia 2026-09-18T10:42:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-alexion-s-efzimfotase-alfa-bla-for-hypophosphatasia 2026-09-18T10:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-padcev-plus-keytruda-for-cisplatin-ineligible-muscle-invasive-bladder-cancer 2026-09-18T09:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-padcev-plus-keytruda-for-cisplatin-ineligible-muscle-invasive-bladder-cancer 2026-09-18T09:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/china-sets-2030-targets-for-drug-innovation-in-new-five-year-pharmaceutical-plan 2026-09-18T08:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-sets-2030-targets-for-drug-innovation-in-new-five-year-pharmaceutical-plan 2026-09-18T08:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-dersimelagon-nda-with-priority-review-as-leo-pharma-closes-tanabe-acquisition 2026-09-18T07:42:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-dersimelagon-nda-with-priority-review-as-leo-pharma-closes-tanabe-acquisition 2026-09-18T07:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-licenses-emicizumab-biosimilar-from-mabxience-adding-first-haemophilia-asset-to-40-drug-pipeline 2026-09-18T07:42:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-licenses-emicizumab-biosimilar-from-mabxience-adding-first-haemophilia-asset-to-40-drug-pipeline 2026-09-18T07:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/bytedance-spin-off-anew-labs-raises-us-290m-for-ai-drug-discovery-models 2026-09-18T06:42:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bytedance-spin-off-anew-labs-raises-us-290m-for-ai-drug-discovery-models 2026-09-18T06:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-sandoz-generic-semaglutide-opening-canada-s-usd-2-6-billion-glp-1-market 2026-09-18T05:42:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-sandoz-generic-semaglutide-opening-canada-s-usd-2-6-billion-glp-1-market 2026-09-18T05:42:21+00:00 hourly 0.9 https://trial.medpath.com/news/electra-raises-350m-ipo-to-fund-registrational-trial-of-ipsoprubart-in-secondary-hlh 2026-09-18T04:42:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/electra-raises-350m-ipo-to-fund-registrational-trial-of-ipsoprubart-in-secondary-hlh 2026-09-18T04:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-halts-potami-61-myelofibrosis-trial 2026-09-18T02:42:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryvu-therapeutics-halts-potami-61-myelofibrosis-trial 2026-09-18T02:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-medtronic-s-ligasure-ras-maryland-vessel-sealer-for-hugo-robotic-surgery-system 2026-09-18T01:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-medtronic-s-ligasure-ras-maryland-vessel-sealer-for-hugo-robotic-surgery-system 2026-09-18T01:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-halts-two-more-ziltivekimab-heart-failure-trials-after-monitoring-committee-signals-futility 2026-09-18T00:42:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-halts-two-more-ziltivekimab-heart-failure-trials-after-monitoring-committee-signals-futility 2026-09-18T00:42:21+00:00 hourly 0.9 https://trial.medpath.com/news/matterhorn-durvalumab-plus-flot-improves-overall-survival-in-resectable-gastric-and-gej-adenocarcinoma 2026-09-17T23:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matterhorn-durvalumab-plus-flot-improves-overall-survival-in-resectable-gastric-and-gej-adenocarcinoma 2026-09-17T23:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-icu-medical-recalls-one-lot-of-0-9-sodium-chloride-injection-after-potassium-chloride-mix-up 2026-09-17T21:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-icu-medical-recalls-one-lot-of-0-9-sodium-chloride-injection-after-potassium-chloride-mix-up 2026-09-17T21:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-submits-azetukalner-nda-to-fda-for-focal-seizures-pauses-psychiatry-enrollment-on-neuropsychiatric-events 2026-09-17T21:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xenon-submits-azetukalner-nda-to-fda-for-focal-seizures-pauses-psychiatry-enrollment-on-neuropsychiatric-events 2026-09-17T21:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-initiates-phase-ii-alisca-lung2-trial-of-alisertib-plus-paclitaxel-in-advanced-small-cell-lung-cancer 2026-09-17T21:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puma-biotechnology-initiates-phase-ii-alisca-lung2-trial-of-alisertib-plus-paclitaxel-in-advanced-small-cell-lung-cancer 2026-09-17T21:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/bms-halts-phase-1-orm-6151-in-aml-and-mds-returning-sole-clinical-stage-dac-to-orum-therapeutics 2026-09-17T20:42:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-halts-phase-1-orm-6151-in-aml-and-mds-returning-sole-clinical-stage-dac-to-orum-therapeutics 2026-09-17T20:42:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-fayuvi-first-ever-gene-therapy-for-sanfilippo-syndrome-type-a 2026-09-17T20:42:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-fayuvi-first-ever-gene-therapy-for-sanfilippo-syndrome-type-a 2026-09-17T20:42:22+00:00 hourly 0.9 https://trial.medpath.com/news/merz-therapeutics-wins-eu-eea-approval-for-xeomin-in-pediatric-pes-equinus-spasticity 2026-09-17T19:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merz-therapeutics-wins-eu-eea-approval-for-xeomin-in-pediatric-pes-equinus-spasticity 2026-09-17T19:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-licenses-preclinical-lrrk2-c-abl-dual-inhibitor-1st-104-for-parkinson-s-in-deal-worth-up-to-314-8m 2026-09-17T18:42:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-licenses-preclinical-lrrk2-c-abl-dual-inhibitor-1st-104-for-parkinson-s-in-deal-worth-up-to-314-8m 2026-09-17T18:42:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-neptune-medical-s-triton-1-robotic-endoscopy-system-for-colon-procedures 2026-09-17T18:42:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-neptune-medical-s-triton-1-robotic-endoscopy-system-for-colon-procedures 2026-09-17T18:42:19+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-health-ministry-restricts-stem-cell-therapy-for-autism-to-approved-clinical-trials 2026-09-17T18:42:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-health-ministry-restricts-stem-cell-therapy-for-autism-to-approved-clinical-trials 2026-09-17T18:42:19+00:00 hourly 0.9 https://trial.medpath.com/news/astro-issues-first-standalone-guideline-on-radiation-therapy-for-bladder-cancer 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astro-issues-first-standalone-guideline-on-radiation-therapy-for-bladder-cancer 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-taletrectinib-label-update-showing-49-7-month-median-duration-of-response-in-ros1-nsclc 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-taletrectinib-label-update-showing-49-7-month-median-duration-of-response-in-ros1-nsclc 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-acquires-marea-therapeutics-in-stock-for-stock-deal-with-225-million-concurrent-financing-to-advance-cardioendocrine-pipeline 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-acquires-marea-therapeutics-in-stock-for-stock-deal-with-225-million-concurrent-financing-to-advance-cardioendocrine-pipeline 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-astrazeneca-s-camizestrant-etcamah-for-esr1-mutant-metastatic-breast-cancer 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-astrazeneca-s-camizestrant-etcamah-for-esr1-mutant-metastatic-breast-cancer 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-daraxonrasib-plus-chemotherapy-for-untreated-metastatic-pancreatic-cancer 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-daraxonrasib-plus-chemotherapy-for-untreated-metastatic-pancreatic-cancer 2026-09-17T17:42:21+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-multiple-myeloma-guidelines-add-dedicated-mrd-testing-page-name-clonoseq-and-set-10-6-as-preferred-sensitivity 2026-09-17T15:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-multiple-myeloma-guidelines-add-dedicated-mrd-testing-page-name-clonoseq-and-set-10-6-as-preferred-sensitivity 2026-09-17T15:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-novo-nordisk-s-frehemgo-denecimig-for-hemophilia-a-setting-up-late-2026-eu-launch 2026-09-17T15:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-novo-nordisk-s-frehemgo-denecimig-for-hemophilia-a-setting-up-late-2026-eu-launch 2026-09-17T15:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-xdc-out-licenses-wuxitecan-2-payload-linker-platform-to-ona-therapeutics-for-first-in-class-adc 2026-09-17T15:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-xdc-out-licenses-wuxitecan-2-payload-linker-platform-to-ona-therapeutics-for-first-in-class-adc 2026-09-17T15:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-denecimig-shows-tolerable-direct-switch-from-emicizumab-in-phase-3b-frontier5-hemophilia-a-study 2026-09-17T14:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-denecimig-shows-tolerable-direct-switch-from-emicizumab-in-phase-3b-frontier5-hemophilia-a-study 2026-09-17T14:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-resubmits-nda-for-anaphylm-sublingual-epinephrine-film-after-crl 2026-09-17T13:42:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aquestive-resubmits-nda-for-anaphylm-sublingual-epinephrine-film-after-crl 2026-09-17T13:42:39+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-and-north-immunology-merge-to-advance-il-13-x-il-18-bispecific-antibody-nor-101-for-atopic-dermatitis 2026-09-17T12:42:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aethlon-and-north-immunology-merge-to-advance-il-13-x-il-18-bispecific-antibody-nor-101-for-atopic-dermatitis 2026-09-17T12:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-updated-ibtrozi-label-with-nearly-50-month-duration-of-response-in-tki-naive-ros1-nsclc 2026-09-17T12:42:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-updated-ibtrozi-label-with-nearly-50-month-duration-of-response-in-tki-naive-ros1-nsclc 2026-09-17T12:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/roche-pays-36-5m-upfront-to-dualitas-for-300000-combination-bispecific-antibody-hunt-in-immunology 2026-09-17T12:42:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-pays-36-5m-upfront-to-dualitas-for-300000-combination-bispecific-antibody-hunt-in-immunology 2026-09-17T12:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/orbis-medicines-and-novo-nordisk-launch-multi-target-oral-macrocycle-discovery-deal-worth-up-to-usd-1-4-billion 2026-09-17T12:42:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orbis-medicines-and-novo-nordisk-launch-multi-target-oral-macrocycle-discovery-deal-worth-up-to-usd-1-4-billion 2026-09-17T12:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-galinpepimut-s-immunotherapy-study-to-end-in-failure 2026-09-17T11:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-galinpepimut-s-immunotherapy-study-to-end-in-failure 2026-09-17T11:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/nice-backs-enhertu-for-her2-low-advanced-breast-cancer-opening-nhs-access-in-england 2026-09-17T10:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-backs-enhertu-for-her2-low-advanced-breast-cancer-opening-nhs-access-in-england 2026-09-17T10:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/os-therapies-aligns-with-fda-mhra-and-ema-on-adaptive-phase-3-design-for-ost-her2-in-metastatic-osteosarcoma 2026-09-17T10:42:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/os-therapies-aligns-with-fda-mhra-and-ema-on-adaptive-phase-3-design-for-ost-her2-in-metastatic-osteosarcoma 2026-09-17T10:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bayer-s-kerendia-for-chronic-kidney-disease-in-type-1-diabetes-first-new-option-in-over-30-years 2026-09-17T09:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bayer-s-kerendia-for-chronic-kidney-disease-in-type-1-diabetes-first-new-option-in-over-30-years 2026-09-17T09:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-to-invest-nearly-200-million-yuan-in-wuxi-site-upgrade-for-cardiovascular-drug-supply 2026-09-17T09:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-to-invest-nearly-200-million-yuan-in-wuxi-site-upgrade-for-cardiovascular-drug-supply 2026-09-17T09:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-s-egfr-trop2-bispecific-adc-ak158d1-wins-nmpa-phase-i-clearance-for-advanced-solid-tumors 2026-09-17T08:42:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-s-egfr-trop2-bispecific-adc-ak158d1-wins-nmpa-phase-i-clearance-for-advanced-solid-tumors 2026-09-17T08:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bayer-s-kerendia-finerenone-for-ckd-associated-with-type-1-diabetes-first-new-option-in-over-30-years 2026-09-17T07:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bayer-s-kerendia-finerenone-for-ckd-associated-with-type-1-diabetes-first-new-option-in-over-30-years 2026-09-17T07:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-lunsumio-lenalidomide-combo-hits-primary-endpoint-in-phase-iii-celestimo-follicular-lymphoma-trial 2026-09-17T07:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-lunsumio-lenalidomide-combo-hits-primary-endpoint-in-phase-iii-celestimo-follicular-lymphoma-trial 2026-09-17T07:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/nice-reverses-decision-enhertu-now-available-on-nhs-england-for-her2-low-metastatic-breast-cancer 2026-09-17T00:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-reverses-decision-enhertu-now-available-on-nhs-england-for-her2-low-metastatic-breast-cancer 2026-09-17T00:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-s-laromestrocel-misses-primary-endpoint-in-elpis-ii-phase-2b-trial-in-hypoplastic-left-heart-syndrome 2026-09-16T23:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longeveron-s-laromestrocel-misses-primary-endpoint-in-elpis-ii-phase-2b-trial-in-hypoplastic-left-heart-syndrome 2026-09-16T23:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/flow-neuroscience-launches-fl-100-in-the-us-as-first-fda-approved-at-home-tdcs-treatment-for-depression 2026-09-16T22:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flow-neuroscience-launches-fl-100-in-the-us-as-first-fda-approved-at-home-tdcs-treatment-for-depression 2026-09-16T22:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-exercises-option-to-acquire-sironax-brain-delivery-platform-for-125m-upfront 2026-09-16T21:42:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-exercises-option-to-acquire-sironax-brain-delivery-platform-for-125m-upfront 2026-09-16T21:42:16+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-retatrutide-shows-unprecedented-weight-loss-in-phase-iii-trial 2026-09-16T21:42:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-retatrutide-shows-unprecedented-weight-loss-in-phase-iii-trial 2026-09-16T21:42:16+00:00 hourly 0.9 https://trial.medpath.com/news/sling-therapeutics-raises-123m-series-c-to-push-oral-thyroid-eye-disease-drug-into-phase-3 2026-09-16T21:42:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sling-therapeutics-raises-123m-series-c-to-push-oral-thyroid-eye-disease-drug-into-phase-3 2026-09-16T21:42:16+00:00 hourly 0.9 https://trial.medpath.com/news/optimi-health-to-launch-health-canada-authorized-phase-3-trial-of-mdma-assisted-therapy-for-ptsd 2026-09-16T16:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optimi-health-to-launch-health-canada-authorized-phase-3-trial-of-mdma-assisted-therapy-for-ptsd 2026-09-16T16:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/sling-therapeutics-doses-first-patients-in-phase-iii-orbit-trial-of-oral-linsitinib-for-thyroid-eye-disease 2026-09-16T16:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sling-therapeutics-doses-first-patients-in-phase-iii-orbit-trial-of-oral-linsitinib-for-thyroid-eye-disease 2026-09-16T16:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-taps-anthropic-s-claude-to-supercharge-ai-driven-drug-discovery 2026-09-16T16:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-taps-anthropic-s-claude-to-supercharge-ai-driven-drug-discovery 2026-09-16T16:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-leqembi-pen-first-at-home-subcutaneous-alzheimer-s-treatment 2026-09-16T15:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-leqembi-pen-first-at-home-subcutaneous-alzheimer-s-treatment 2026-09-16T15:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/alkem-launches-neuceno-cenobamate-in-india-first-availability-of-the-anti-seizure-drug-for-partial-onset-seizures 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkem-launches-neuceno-cenobamate-in-india-first-availability-of-the-anti-seizure-drug-for-partial-onset-seizures 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-doses-first-u-s-patient-in-phase-2-thio-101-expansion-of-telomere-targeting-ateganosine-in-third-line-nsclc 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-doses-first-u-s-patient-in-phase-2-thio-101-expansion-of-telomere-targeting-ateganosine-in-third-line-nsclc 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-exercises-option-to-acquire-sironax-brain-delivery-platform-for-125-million 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-exercises-option-to-acquire-sironax-brain-delivery-platform-for-125-million 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-halts-als-program-after-vhb937-misses-primary-and-secondary-endpoints-in-phase-2-astrals-trial 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-halts-als-program-after-vhb937-misses-primary-and-secondary-endpoints-in-phase-2-astrals-trial 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-and-bms-pause-autoimmune-car-t-trials-over-safety-concerns 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-and-bms-pause-autoimmune-car-t-trials-over-safety-concerns 2026-09-16T14:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-reports-clinical-proof-of-mechanism-for-fap-activated-exatecan-pdc-ava6103-in-phase-1-focus-01 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-reports-clinical-proof-of-mechanism-for-fap-activated-exatecan-pdc-ava6103-in-phase-1-focus-01 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-and-torii-win-japanese-approval-for-vtama-cream-0-5-in-pediatric-atopic-dermatitis 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-and-torii-win-japanese-approval-for-vtama-cream-0-5-in-pediatric-atopic-dermatitis 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-viatris-wakix-pitolisant-first-histamine-h3-receptor-antagonist-for-narcolepsy-and-osa-related-daytime-sleepiness 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-viatris-wakix-pitolisant-first-histamine-h3-receptor-antagonist-for-narcolepsy-and-osa-related-daytime-sleepiness 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-oncoc4-s-pd-1-vegf-bispecific-cesalatamig-for-pd-l-1-refractory-nsclc 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-oncoc4-s-pd-1-vegf-bispecific-cesalatamig-for-pd-l-1-refractory-nsclc 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/splisense-initiates-phase-2b-trial-of-inhaled-aso-spl84-as-add-on-to-cftr-modulators-in-cystic-fibrosis 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splisense-initiates-phase-2b-trial-of-inhaled-aso-spl84-as-add-on-to-cftr-modulators-in-cystic-fibrosis 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-foundationone-cdx-as-companion-diagnostic-for-tovorafenib-in-braf-altered-glioma 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-foundationone-cdx-as-companion-diagnostic-for-tovorafenib-in-braf-altered-glioma 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-iaso208-first-china-originated-in-vivo-car-t-to-enter-us-clinic 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-iaso208-first-china-originated-in-vivo-car-t-to-enter-us-clinic 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-ono-sue-amgen-to-block-proposed-opdivo-biosimilar-in-us 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-and-ono-sue-amgen-to-block-proposed-opdivo-biosimilar-in-us 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/rusfertide-approved-for-polycythemia-vera 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rusfertide-approved-for-polycythemia-vera 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/japan-s-mhlw-approves-lundbeck-s-vyepti-eptinezumab-the-only-iv-cgrp-targeted-migraine-preventive-in-the-country 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-s-mhlw-approves-lundbeck-s-vyepti-eptinezumab-the-only-iv-cgrp-targeted-migraine-preventive-in-the-country 2026-09-16T13:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/harmoni-2-ivonescimab-cuts-death-risk-27-versus-pembrolizumab-in-first-line-pd-l1-positive-nsclc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmoni-2-ivonescimab-cuts-death-risk-27-versus-pembrolizumab-in-first-line-pd-l1-positive-nsclc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-to-start-phase-ii-oral-ebola-trial-in-drc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-to-start-phase-ii-oral-ebola-trial-in-drc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/immunocore-completes-enrollment-in-registrational-tebe-am-trial-of-kimmtrak-in-advanced-melanoma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocore-completes-enrollment-in-registrational-tebe-am-trial-of-kimmtrak-in-advanced-melanoma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/lancet-modeling-study-warns-medicare-most-favored-nation-pricing-could-reshape-global-drug-launch-strategy 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lancet-modeling-study-warns-medicare-most-favored-nation-pricing-could-reshape-global-drug-launch-strategy 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-imposes-claims-data-reporting-requirement-on-340b-providers-threatening-discount-suspension 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-imposes-claims-data-reporting-requirement-on-340b-providers-threatening-discount-suspension 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/updated-harmoni-data-at-wclc-2026-show-durable-overall-survival-benefit-for-ivonescimab-in-egfr-mutated-nsclc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-harmoni-data-at-wclc-2026-show-durable-overall-survival-benefit-for-ivonescimab-in-egfr-mutated-nsclc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/shandong-boan-biotechnology-receives-cde-ind-clearance-for-ba1203 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shandong-boan-biotechnology-receives-cde-ind-clearance-for-ba1203 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-united-therapeutics-supplemental-nda-for-nebulized-tyvaso-in-ipf-with-decision-expected-in-late-april-2027 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-united-therapeutics-supplemental-nda-for-nebulized-tyvaso-in-ipf-with-decision-expected-in-late-april-2027 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-wins-egyptian-drug-authority-approval-for-kisqali-as-adjuvant-therapy-in-early-breast-cancer 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-wins-egyptian-drug-authority-approval-for-kisqali-as-adjuvant-therapy-in-early-breast-cancer 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/ocular-therapeutix-clears-fda-pre-nda-meeting-for-axpaxli-in-wet-amd-nda-submission-on-track-for-q4-2026 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocular-therapeutix-clears-fda-pre-nda-meeting-for-axpaxli-in-wet-amd-nda-submission-on-track-for-q4-2026 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/montana-opens-experimental-drug-access-through-privately-run-review-board 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montana-opens-experimental-drug-access-through-privately-run-review-board 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/skyhawk-s-sky-0515-shows-1-59-point-cuhdrs-advantage-at-15-months-in-huntington-s-disease 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skyhawk-s-sky-0515-shows-1-59-point-cuhdrs-advantage-at-15-months-in-huntington-s-disease 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-oral-obesity-drug-foundayo-captures-over-30-of-new-us-patients-challenging-novo-s-wegovy-pill 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-oral-obesity-drug-foundayo-captures-over-30-of-new-us-patients-challenging-novo-s-wegovy-pill 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-tuhura-s-ind-for-tbs-2025-a-first-in-class-vista-inhibiting-antibody-in-mutnpm1-aml 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-tuhura-s-ind-for-tbs-2025-a-first-in-class-vista-inhibiting-antibody-in-mutnpm1-aml 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-wins-fda-approval-for-first-metered-dose-inhaler-generic-beclomethasone-aerosol 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-wins-fda-approval-for-first-metered-dose-inhaler-generic-beclomethasone-aerosol 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-s-rad101-pet-imaging-hits-primary-endpoint-in-phase-2b-brain-metastases-trial-data-selected-for-sno26-late-breaker 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharm-s-rad101-pet-imaging-hits-primary-endpoint-in-phase-2b-brain-metastases-trial-data-selected-for-sno26-late-breaker 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-oral-cb1-inverse-agonist-crb-913-delivers-5-weight-loss-at-12-weeks-in-phase-1b-canyon-1-trial 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corbus-oral-cb1-inverse-agonist-crb-913-delivers-5-weight-loss-at-12-weeks-in-phase-1b-canyon-1-trial 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-completes-820m-actio-biosciences-acquisition-adding-first-in-class-kcnt1-epilepsy-candidate-abs-1230 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-completes-820m-actio-biosciences-acquisition-adding-first-in-class-kcnt1-epilepsy-candidate-abs-1230 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-launches-u-s-phase-4-trial-of-240mg-high-dose-zymfentra-in-crohn-s-and-ulcerative-colitis 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-launches-u-s-phase-4-trial-of-240mg-high-dose-zymfentra-in-crohn-s-and-ulcerative-colitis 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/blossomhill-s-omni-egfr-inhibitor-bh-30643-yields-45-orr-in-c797s-positive-nsclc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blossomhill-s-omni-egfr-inhibitor-bh-30643-yields-45-orr-in-c797s-positive-nsclc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-moves-10-self-imported-medicines-into-government-emergency-import-program 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-moves-10-self-imported-medicines-into-government-emergency-import-program 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-curium-s-bexlutry-first-generic-radioligand-challenging-lutathera-s-gep-net-monopoly 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-curium-s-bexlutry-first-generic-radioligand-challenging-lutathera-s-gep-net-monopoly 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/tempest-therapeutics-secures-exclusive-option-to-senlang-s-cd7-targeted-lentiviral-in-vivo-car-t-platform-and-bcma-gprc5d-candidate 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempest-therapeutics-secures-exclusive-option-to-senlang-s-cd7-targeted-lentiviral-in-vivo-car-t-platform-and-bcma-gprc5d-candidate 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/genfleet-s-oral-kras-g12d-inhibitor-gfh375-posts-strong-phase-ii-results-in-pretreated-nsclc-paving-way-for-first-global-phase-iii 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfleet-s-oral-kras-g12d-inhibitor-gfh375-posts-strong-phase-ii-results-in-pretreated-nsclc-paving-way-for-first-global-phase-iii 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/axoltis-reports-phase-2-failure-of-experimental-als-drug 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axoltis-reports-phase-2-failure-of-experimental-als-drug 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/elevar-submits-ema-marketing-authorization-application-for-lirafugratinib-in-fgfr2-fusion-cholangiocarcinoma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevar-submits-ema-marketing-authorization-application-for-lirafugratinib-in-fgfr2-fusion-cholangiocarcinoma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/canada-approves-multiple-denosumab-and-ustekinumab-biosimilars-as-global-competition-intensifies 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-approves-multiple-denosumab-and-ustekinumab-biosimilars-as-global-competition-intensifies 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/taletrectinib-shows-consistent-efficacy-across-ros1-nsclc-subgroups-regardless-of-prior-chemotherapy-or-fusion-partner 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taletrectinib-shows-consistent-efficacy-across-ros1-nsclc-subgroups-regardless-of-prior-chemotherapy-or-fusion-partner 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/os-therapies-gains-full-mhra-and-ema-alignment-on-conditional-marketing-applications-for-ost-her2-in-osteosarcoma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/os-therapies-gains-full-mhra-and-ema-alignment-on-conditional-marketing-applications-for-ost-her2-in-osteosarcoma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-expedited-ind-pilot-with-rolling-review-to-speed-first-in-human-trials 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-expedited-ind-pilot-with-rolling-review-to-speed-first-in-human-trials 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/saol-therapeutics-secures-up-to-115m-from-oaktree-to-prepare-sl1009-launch-in-pdcd 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saol-therapeutics-secures-up-to-115m-from-oaktree-to-prepare-sl1009-launch-in-pdcd 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-cogent-biosciences-nda-for-bezuclastinib-in-advanced-systemic-mastocytosis-pdufa-set-for-june-2027 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-cogent-biosciences-nda-for-bezuclastinib-in-advanced-systemic-mastocytosis-pdufa-set-for-june-2027 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/biovie-s-bezisterim-misses-significance-in-full-long-covid-population-but-shows-phase-2-subgroup-signal 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovie-s-bezisterim-misses-significance-in-full-long-covid-population-but-shows-phase-2-subgroup-signal 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/vera-s-trutakna-stabilizes-egfr-and-cuts-igan-progression-risk-76-in-final-origin-3-analysis 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vera-s-trutakna-stabilizes-egfr-and-cuts-igan-progression-risk-76-in-final-origin-3-analysis 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-s-xervyteg-hits-negative-chmp-trend-vote-in-re-examination-for-agvhd-approval 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-s-xervyteg-hits-negative-chmp-trend-vote-in-re-examination-for-agvhd-approval 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-convenes-landmark-public-hearing-on-psychedelic-therapeutics-as-agency-finalizes-regulatory-framework 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-convenes-landmark-public-hearing-on-psychedelic-therapeutics-as-agency-finalizes-regulatory-framework 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/hlb-s-elevar-submits-ema-marketing-application-for-lirafugratinib-in-fgfr2-driven-cholangiocarcinoma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hlb-s-elevar-submits-ema-marketing-application-for-lirafugratinib-in-fgfr2-driven-cholangiocarcinoma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-pays-up-to-750m-for-chimagen-trispecific-t-cell-engager-in-multiple-myeloma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-pays-up-to-750m-for-chimagen-trispecific-t-cell-engager-in-multiple-myeloma 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-daraxonrasib-plus-chemotherapy-in-first-line-metastatic-pancreatic-cancer 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-daraxonrasib-plus-chemotherapy-in-first-line-metastatic-pancreatic-cancer 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-m1-antagonist-pipe-307-misses-primary-endpoint-in-phase-2-mdd-trial-second-setback-for-the-molecule 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-m1-antagonist-pipe-307-misses-primary-endpoint-in-phase-2-mdd-trial-second-setback-for-the-molecule 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-doses-first-patient-in-phase-2-basket-trial-of-ebribafusp-for-rare-complement-mediated-kidney-diseases 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akebia-doses-first-patient-in-phase-2-basket-trial-of-ebribafusp-for-rare-complement-mediated-kidney-diseases 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/revelyx-bio-s-yy003-hits-phase-2-endpoints-in-glabellar-lines-eyes-fda-end-of-phase-2-meeting 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revelyx-bio-s-yy003-hits-phase-2-endpoints-in-glabellar-lines-eyes-fda-end-of-phase-2-meeting 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/lipocine-launches-second-phase-3-bloom-trial-of-oral-brexanolone-lpcn-1154-in-postpartum-depression-after-first-pivotal-study-missed-endpoint 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipocine-launches-second-phase-3-bloom-trial-of-oral-brexanolone-lpcn-1154-in-postpartum-depression-after-first-pivotal-study-missed-endpoint 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-tenaya-s-tn-401-gene-therapy-for-pkp2-associated-arvc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-tenaya-s-tn-401-gene-therapy-for-pkp2-associated-arvc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/entropy-neurodynamics-reports-durable-12-week-response-with-trp-8803-in-treatment-resistant-binge-eating-disorder 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entropy-neurodynamics-reports-durable-12-week-response-with-trp-8803-in-treatment-resistant-binge-eating-disorder 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-reduced-monitoring-time-for-first-two-imdelltra-doses-in-es-sclc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-reduced-monitoring-time-for-first-two-imdelltra-doses-in-es-sclc 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/accro-bioscience-s-ac-101-tablets-enter-nmpa-cde-caring-plan-extension-pilot-for-blau-syndrome 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accro-bioscience-s-ac-101-tablets-enter-nmpa-cde-caring-plan-extension-pilot-for-blau-syndrome 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-opens-expedited-ind-pilot-with-rolling-pre-ind-review-to-cut-first-in-human-timelines 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-opens-expedited-ind-pilot-with-rolling-pre-ind-review-to-cut-first-in-human-timelines 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reclassifies-nrx-pharmaceuticals-anda-amendment-for-preservative-free-ketamine-as-minor-setting-gdufa-goal-date-of-november-10-2026 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reclassifies-nrx-pharmaceuticals-anda-amendment-for-preservative-free-ketamine-as-minor-setting-gdufa-goal-date-of-november-10-2026 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/ema-validates-marketing-application-for-pfizer-valneva-lyme-vaccine-pf-07307405 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-validates-marketing-application-for-pfizer-valneva-lyme-vaccine-pf-07307405 2026-09-16T12:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-abelzeta-ind-for-phase-1b-2-trial-of-bispecific-car-t-c-car168-in-progressive-multiple-sclerosis 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-abelzeta-ind-for-phase-1b-2-trial-of-bispecific-car-t-c-car168-in-progressive-multiple-sclerosis 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/dsmb-clears-briacell-s-phase-3-bria-abc-study-of-bria-imt-plus-checkpoint-inhibitor-for-seventh-straight-time 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dsmb-clears-briacell-s-phase-3-bria-abc-study-of-bria-imt-plus-checkpoint-inhibitor-for-seventh-straight-time 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-pd-l1-4-1bb-bispecific-opamtistomig-delivers-71-orr-in-first-line-nsclc-at-wclc-2026 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leads-biolabs-pd-l1-4-1bb-bispecific-opamtistomig-delivers-71-orr-in-first-line-nsclc-at-wclc-2026 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/perspective-therapeutics-merck-partner-to-test-212pb-psv359-plus-keytruda-in-fap-a-positive-solid-tumors 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perspective-therapeutics-merck-partner-to-test-212pb-psv359-plus-keytruda-in-fap-a-positive-solid-tumors 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-armata-s-phage-therapy-ap-sa02-for-complicated-s-aureus-bacteremia 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-armata-s-phage-therapy-ap-sa02-for-complicated-s-aureus-bacteremia 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/cellectis-exits-allogeneic-car-t-development-pivots-to-in-vivo-gene-editing-for-severe-dyslipidemias 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectis-exits-allogeneic-car-t-development-pivots-to-in-vivo-gene-editing-for-severe-dyslipidemias 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/nanobiotix-reports-full-cohort-phase-1-results-for-jnj-1900-nbtxr3-in-recurrent-nsclc-re-irradiation 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanobiotix-reports-full-cohort-phase-1-results-for-jnj-1900-nbtxr3-in-recurrent-nsclc-re-irradiation 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/definium-s-dt120-odt-hits-primary-endpoint-in-second-phase-3-gad-win-setting-up-first-psychedelic-nda-for-anxiety 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/definium-s-dt120-odt-hits-primary-endpoint-in-second-phase-3-gad-win-setting-up-first-psychedelic-nda-for-anxiety 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/b7-h3-adc-ris-rez-cuts-death-risk-54-in-relapsed-small-cell-lung-cancer 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b7-h3-adc-ris-rez-cuts-death-risk-54-in-relapsed-small-cell-lung-cancer 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/trastuzumab-botidotin-triples-median-pfs-versus-t-dm1-in-phase-iii-her2-positive-breast-cancer-trial-published-in-jco 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trastuzumab-botidotin-triples-median-pfs-versus-t-dm1-in-phase-iii-her2-positive-breast-cancer-trial-published-in-jco 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/zipalertinib-plus-chemotherapy-cuts-progression-risk-50-in-first-line-egfr-exon-20-insertion-nsclc 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zipalertinib-plus-chemotherapy-cuts-progression-risk-50-in-first-line-egfr-exon-20-insertion-nsclc 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/zidesamtinib-delivers-94-response-rate-in-tki-naive-ros1-positive-nsclc-supporting-first-line-filing 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zidesamtinib-delivers-94-response-rate-in-tki-naive-ros1-positive-nsclc-supporting-first-line-filing 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/gotistobart-nearly-doubles-median-overall-survival-in-previously-treated-squamous-nsclc-in-phase-3-preserve-003-stage-1 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gotistobart-nearly-doubles-median-overall-survival-in-previously-treated-squamous-nsclc-in-phase-3-preserve-003-stage-1 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-takeda-s-zasocitinib-nda-under-priority-review-for-moderate-to-severe-plaque-psoriasis 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-takeda-s-zasocitinib-nda-under-priority-review-for-moderate-to-severe-plaque-psoriasis 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/papillon-final-analysis-amivantamab-plus-chemotherapy-delivers-34-3-month-median-os-in-egfr-exon-20-insertion-nsclc 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/papillon-final-analysis-amivantamab-plus-chemotherapy-delivers-34-3-month-median-os-in-egfr-exon-20-insertion-nsclc 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/enhertu-cuts-progression-risk-37-in-first-line-her2-mutant-nsclc-delivering-14-3-month-median-pfs-in-destiny-lung04 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhertu-cuts-progression-risk-37-in-first-line-her2-mutant-nsclc-delivering-14-3-month-median-pfs-in-destiny-lung04 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/papillon-final-analysis-rybrevant-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-nsclc 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/papillon-final-analysis-rybrevant-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-nsclc 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-telix-s-pixclara-first-fet-pet-imaging-drug-for-glioma-in-the-u-s 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-telix-s-pixclara-first-fet-pet-imaging-drug-for-glioma-in-the-u-s 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/definium-therapeutics-to-report-phase-3-panorama-topline-results-for-lsd-based-anxiety-drug-dt120 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/definium-therapeutics-to-report-phase-3-panorama-topline-results-for-lsd-based-anxiety-drug-dt120 2026-09-16T11:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-to-phase-in-medication-abortion-up-to-nine-weeks-by-early-2027 2026-09-16T07:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-to-phase-in-medication-abortion-up-to-nine-weeks-by-early-2027 2026-09-16T07:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/cambium-bio-raises-a-10-85m-to-launch-pivotal-phase-3-trial-of-elate-ocular-in-dry-eye-disease 2026-09-16T05:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambium-bio-raises-a-10-85m-to-launch-pivotal-phase-3-trial-of-elate-ocular-in-dry-eye-disease 2026-09-16T05:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-reports-positive-phase-3-abtect-8-week-induction-results-for-obefazimod-in-ulcerative-colitis 2026-09-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-reports-positive-phase-3-abtect-8-week-induction-results-for-obefazimod-in-ulcerative-colitis 2026-09-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bexlutry-first-generic-radioligand-therapy-after-curium-wins-novartis-patent-dispute 2026-09-15T21:53:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bexlutry-first-generic-radioligand-therapy-after-curium-wins-novartis-patent-dispute 2026-09-15T21:53:37+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-gives-7-5m-to-blood-cancer-united-s-therapy-acceleration-program-marking-new-venture-philanthropy-phase 2026-09-15T21:53:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royalty-pharma-gives-7-5m-to-blood-cancer-united-s-therapy-acceleration-program-marking-new-venture-philanthropy-phase 2026-09-15T21:53:06+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-alphagenome-atlas-maps-all-9-billion-single-letter-genetic-variants-extending-alphafold-era-push-into-disease-detection 2026-09-15T19:50:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-alphagenome-atlas-maps-all-9-billion-single-letter-genetic-variants-extending-alphafold-era-push-into-disease-detection 2026-09-15T19:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/ori-biotech-signs-10-year-120m-deal-to-move-a-commercial-cell-therapy-onto-its-iro-platform 2026-09-15T17:50:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ori-biotech-signs-10-year-120m-deal-to-move-a-commercial-cell-therapy-onto-its-iro-platform 2026-09-15T17:50:01+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-launches-14-05m-we-cair-program-to-decode-wildfire-smoke-s-cardiovascular-and-airway-damage 2026-09-15T17:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-launches-14-05m-we-cair-program-to-decode-wildfire-smoke-s-cardiovascular-and-airway-damage 2026-09-15T17:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/regcell-raises-66m-to-advance-nobel-winning-treg-cell-therapy-into-clinic 2026-09-15T17:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regcell-raises-66m-to-advance-nobel-winning-treg-cell-therapy-into-clinic 2026-09-15T17:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-hsa-flag-vitamin-b6-deficiency-and-seizure-risk-with-carbidopa-levodopa-and-benserazide-levodopa 2026-09-15T16:51:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-hsa-flag-vitamin-b6-deficiency-and-seizure-risk-with-carbidopa-levodopa-and-benserazide-levodopa 2026-09-15T16:51:38+00:00 hourly 0.9 https://trial.medpath.com/news/novel-small-molecule-mwac-3634-stabilizes-ebola-entry-protein-blocks-infection-at-0-65-nm 2026-09-15T16:50:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-small-molecule-mwac-3634-stabilizes-ebola-entry-protein-blocks-infection-at-0-65-nm 2026-09-15T16:50:31+00:00 hourly 0.9 https://trial.medpath.com/news/openai-foundation-grants-unc-lineberger-40m-to-sharpen-personalized-cancer-vaccine-design 2026-09-15T16:50:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/openai-foundation-grants-unc-lineberger-40m-to-sharpen-personalized-cancer-vaccine-design 2026-09-15T16:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-launches-nivorz-india-s-in-house-nivolumab-biosimilar-across-12-oncology-indications 2026-09-15T16:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-launches-nivorz-india-s-in-house-nivolumab-biosimilar-across-12-oncology-indications 2026-09-15T16:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/evvy-raises-40m-series-b-to-scale-ai-driven-vaginal-microbiome-diagnostics-and-enter-fertility 2026-09-15T16:50:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evvy-raises-40m-series-b-to-scale-ai-driven-vaginal-microbiome-diagnostics-and-enter-fertility 2026-09-15T16:50:01+00:00 hourly 0.9 https://trial.medpath.com/news/remedy-plan-advances-first-in-class-hyperbolic-nampt-inhibitor-rpt1g-into-cohort-2-in-r-r-aml-and-hr-mds-fda-accepts-solid-tumor-ind 2026-09-15T16:49:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remedy-plan-advances-first-in-class-hyperbolic-nampt-inhibitor-rpt1g-into-cohort-2-in-r-r-aml-and-hr-mds-fda-accepts-solid-tumor-ind 2026-09-15T16:49:56+00:00 hourly 0.9 https://trial.medpath.com/news/hexembio-raises-15-5m-to-advance-stem-cell-rejuvenation-platform-into-three-product-generations 2026-09-15T14:50:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hexembio-raises-15-5m-to-advance-stem-cell-rejuvenation-platform-into-three-product-generations 2026-09-15T14:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/revive-therapeutics-to-expand-bucillamine-ip-and-orphan-drug-portfolio-across-medical-countermeasures-and-rare-diseases 2026-09-15T14:49:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revive-therapeutics-to-expand-bucillamine-ip-and-orphan-drug-portfolio-across-medical-countermeasures-and-rare-diseases 2026-09-15T14:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/elvinix-licenses-zealand-pharma-s-glp-1-gastrin-dual-agonist-peptides-for-beta-cell-regeneration-in-type-1-diabetes 2026-09-15T14:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elvinix-licenses-zealand-pharma-s-glp-1-gastrin-dual-agonist-peptides-for-beta-cell-regeneration-in-type-1-diabetes 2026-09-15T14:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/imvax-s-igv-001-shows-40-survival-gain-in-unmethylated-mgmt-glioblastoma-subgroup-fda-aligns-on-phase-3-design 2026-09-15T13:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imvax-s-igv-001-shows-40-survival-gain-in-unmethylated-mgmt-glioblastoma-subgroup-fda-aligns-on-phase-3-design 2026-09-15T13:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-kestrel-s-oral-pan-kras-inhibitor-kst-6051-for-kras-mutant-solid-tumors 2026-09-15T13:48:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-kestrel-s-oral-pan-kras-inhibitor-kst-6051-for-kras-mutant-solid-tumors 2026-09-15T13:48:43+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-bioprocess-debuts-vantij-su-vfc-benchtop-for-automated-single-use-virus-filtration-in-gene-therapy-manufacturing 2026-09-15T12:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asahi-kasei-bioprocess-debuts-vantij-su-vfc-benchtop-for-automated-single-use-virus-filtration-in-gene-therapy-manufacturing 2026-09-15T12:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-buphenyl-sodium-phenylbutyrate-for-pfic-types-1-and-2-after-20-year-research-effort 2026-09-15T12:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-buphenyl-sodium-phenylbutyrate-for-pfic-types-1-and-2-after-20-year-research-effort 2026-09-15T12:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/one04-therapeutics-launches-on-encouraging-cpv-104-phase-1-interim-data-in-c3-glomerulopathy 2026-09-15T11:48:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one04-therapeutics-launches-on-encouraging-cpv-104-phase-1-interim-data-in-c3-glomerulopathy 2026-09-15T11:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/immupharma-s-p140-cuts-inflammation-and-fibrosis-in-mash-model-as-company-files-international-patent-for-type-m-precision-medicine 2026-09-15T11:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immupharma-s-p140-cuts-inflammation-and-fibrosis-in-mash-model-as-company-files-international-patent-for-type-m-precision-medicine 2026-09-15T11:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/lobe-sciences-to-present-phase-1a-low-dose-psilocin-data-for-l-130-at-neuropsychiatric-drug-development-summit 2026-09-15T10:49:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lobe-sciences-to-present-phase-1a-low-dose-psilocin-data-for-l-130-at-neuropsychiatric-drug-development-summit 2026-09-15T10:49:02+00:00 hourly 0.9 https://trial.medpath.com/news/scaffold-free-3d-cell-culture-market-poised-for-growth-through-2033-as-labs-seek-physiologically-relevant-in-vitro-models 2026-09-15T10:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scaffold-free-3d-cell-culture-market-poised-for-growth-through-2033-as-labs-seek-physiologically-relevant-in-vitro-models 2026-09-15T10:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/nih-backs-12-8m-multi-university-project-to-model-how-female-hormones-alter-drug-processing 2026-09-15T04:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-backs-12-8m-multi-university-project-to-model-how-female-hormones-alter-drug-processing 2026-09-15T04:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-and-massachusetts-general-hospital-partner-to-build-predictive-nose-to-brain-screening-platform-for-cns-drugs 2026-09-15T01:48:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-and-massachusetts-general-hospital-partner-to-build-predictive-nose-to-brain-screening-platform-for-cns-drugs 2026-09-15T01:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/bipartisan-bill-would-make-rare-pediatric-disease-drug-incentive-program-permanent 2026-09-15T00:56:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bipartisan-bill-would-make-rare-pediatric-disease-drug-incentive-program-permanent 2026-09-15T00:56:02+00:00 hourly 0.9 https://trial.medpath.com/news/senseonics-and-beta-bionics-partner-to-integrate-eversense-365-with-ilet-bionic-pancreas 2026-09-15T00:55:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senseonics-and-beta-bionics-partner-to-integrate-eversense-365-with-ilet-bionic-pancreas 2026-09-15T00:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/beta-bionics-wins-fda-clearance-for-mint-patch-pump-submits-3d-intelligence-insulin-dosing-algorithm 2026-09-15T00:55:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beta-bionics-wins-fda-clearance-for-mint-patch-pump-submits-3d-intelligence-insulin-dosing-algorithm 2026-09-15T00:55:42+00:00 hourly 0.9 https://trial.medpath.com/news/ou-health-campus-launches-ai-push-to-tackle-oklahoma-s-bottom-tier-health-outcomes 2026-09-14T22:54:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ou-health-campus-launches-ai-push-to-tackle-oklahoma-s-bottom-tier-health-outcomes 2026-09-14T22:54:35+00:00 hourly 0.9 https://trial.medpath.com/news/updated-mrna-covid-19-vaccines-roll-out-at-united-family-pharmacies-ahead-of-respiratory-virus-season 2026-09-14T21:50:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-mrna-covid-19-vaccines-roll-out-at-united-family-pharmacies-ahead-of-respiratory-virus-season 2026-09-14T21:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/adme-toxicology-testing-market-outlook-2026-2030-north-america-leads-as-asia-pacific-emerges-as-fastest-growing-region 2026-09-14T17:49:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adme-toxicology-testing-market-outlook-2026-2030-north-america-leads-as-asia-pacific-emerges-as-fastest-growing-region 2026-09-14T17:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/santa-ana-bio-doses-first-cohort-in-phase-1-trial-of-kit-siglec-6-bispecific-antibody-sab01-for-mast-cell-depletion 2026-09-14T16:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/santa-ana-bio-doses-first-cohort-in-phase-1-trial-of-kit-siglec-6-bispecific-antibody-sab01-for-mast-cell-depletion 2026-09-14T16:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-to-divest-20-mature-medicines-and-three-manufacturing-sites-to-cheplapharm-in-equity-linked-partnership 2026-09-14T16:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-to-divest-20-mature-medicines-and-three-manufacturing-sites-to-cheplapharm-in-equity-linked-partnership 2026-09-14T16:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/penn-state-health-s-food-as-medicine-initiative-links-24-gardens-six-community-fridges-to-diet-related-disease-research 2026-09-14T15:49:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-state-health-s-food-as-medicine-initiative-links-24-gardens-six-community-fridges-to-diet-related-disease-research 2026-09-14T15:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/resother-s-annexin-a1-mimetic-rtp-026-shows-8-point-lvef-gain-in-phase-2a-stemi-trial-clearing-acquisition-hurdle 2026-09-14T15:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resother-s-annexin-a1-mimetic-rtp-026-shows-8-point-lvef-gain-in-phase-2a-stemi-trial-clearing-acquisition-hurdle 2026-09-14T15:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/alveus-doses-first-patient-in-phase-2-preserve-trial-of-alv-100-for-weight-maintenance-after-semaglutide 2026-09-14T14:49:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alveus-doses-first-patient-in-phase-2-preserve-trial-of-alv-100-for-weight-maintenance-after-semaglutide 2026-09-14T14:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-biofrontera-s-ameluz-red-light-pdt-for-superficial-basal-cell-carcinoma 2026-09-14T14:49:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-biofrontera-s-ameluz-red-light-pdt-for-superficial-basal-cell-carcinoma 2026-09-14T14:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/us-weight-loss-drug-trial-reports-breakthrough-with-fewer-side-effects 2026-09-14T14:49:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-weight-loss-drug-trial-reports-breakthrough-with-fewer-side-effects 2026-09-14T14:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-organon-s-snda-to-extend-hormone-free-iud-miudella-to-six-years-of-use 2026-09-14T13:51:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-organon-s-snda-to-extend-hormone-free-iud-miudella-to-six-years-of-use 2026-09-14T13:51:21+00:00 hourly 0.9 https://trial.medpath.com/news/china-nmpa-accepts-bla-for-longbio-s-anti-ige-antibody-lp-003-in-seasonal-allergic-rhinitis 2026-09-14T13:51:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-nmpa-accepts-bla-for-longbio-s-anti-ige-antibody-lp-003-in-seasonal-allergic-rhinitis 2026-09-14T13:51:05+00:00 hourly 0.9 https://trial.medpath.com/news/shennon-biotechnologies-raises-12m-names-cyril-konto-ceo-and-unveils-three-t-cell-engager-programs 2026-09-14T13:51:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shennon-biotechnologies-raises-12m-names-cyril-konto-ceo-and-unveils-three-t-cell-engager-programs 2026-09-14T13:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-ipn60330-first-mait-cell-engager-paving-way-for-phase-1-in-solid-tumors 2026-09-14T13:51:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-ipn60330-first-mait-cell-engager-paving-way-for-phase-1-in-solid-tumors 2026-09-14T13:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases-with-two-novel-treatment-concepts 2026-09-14T13:51:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases-with-two-novel-treatment-concepts 2026-09-14T13:51:02+00:00 hourly 0.9 https://trial.medpath.com/news/geneuro-wins-european-patent-for-gnk-301-an-anti-herv-k-antibody-targeting-als 2026-09-14T13:50:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneuro-wins-european-patent-for-gnk-301-an-anti-herv-k-antibody-targeting-als 2026-09-14T13:50:25+00:00 hourly 0.9 https://trial.medpath.com/news/love-serving-autism-brings-young-athletes-with-autism-to-center-court-at-the-us-open 2026-09-14T13:50:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/love-serving-autism-brings-young-athletes-with-autism-to-center-court-at-the-us-open 2026-09-14T13:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-orexo-s-ind-for-needle-free-intranasal-epinephrine-powder-ox640-in-anaphylaxis 2026-09-14T10:42:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-orexo-s-ind-for-needle-free-intranasal-epinephrine-powder-ox640-in-anaphylaxis 2026-09-14T10:42:04+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-osimertinib-delivers-unprecedented-8-year-overall-survival-benefit-in-resected-egfr-mutated-nsclc 2026-09-14T08:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-osimertinib-delivers-unprecedented-8-year-overall-survival-benefit-in-resected-egfr-mutated-nsclc 2026-09-14T08:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/whitehawk-data-at-wclc-2026-position-ptk7-as-durable-treatment-agnostic-adc-target-in-egfr-wild-type-nsclc 2026-09-14T02:48:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whitehawk-data-at-wclc-2026-position-ptk7-as-durable-treatment-agnostic-adc-target-in-egfr-wild-type-nsclc 2026-09-14T02:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/huons-wins-three-state-drug-development-grants-to-advance-mrna-eye-drop-adc-and-peptide-cancer-drug 2026-09-14T02:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huons-wins-three-state-drug-development-grants-to-advance-mrna-eye-drop-adc-and-peptide-cancer-drug 2026-09-14T02:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/falls-in-older-adults-14-million-report-falling-annually-as-clinicians-push-prevention-over-inevitability 2026-09-14T00:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/falls-in-older-adults-14-million-report-falling-annually-as-clinicians-push-prevention-over-inevitability 2026-09-14T00:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-s-seelyra-femtosecond-laser-wins-european-ce-mark 2026-09-13T20:48:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-s-seelyra-femtosecond-laser-wins-european-ce-mark 2026-09-13T20:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/medipal-and-jcr-dose-first-patient-in-global-phase-i-ii-trial-of-jr-446-for-sanfilippo-syndrome-type-b 2026-09-13T19:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipal-and-jcr-dose-first-patient-in-global-phase-i-ii-trial-of-jr-446-for-sanfilippo-syndrome-type-b 2026-09-13T19:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/tatyana-ali-turns-traumatic-birth-into-advocacy-for-black-and-indigenous-maternal-health 2026-09-13T16:48:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tatyana-ali-turns-traumatic-birth-into-advocacy-for-black-and-indigenous-maternal-health 2026-09-13T16:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-maverick-trial-backs-brain-mri-surveillance-alone-dropping-prophylactic-cranial-irradiation-in-sclc 2026-09-13T13:49:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-maverick-trial-backs-brain-mri-surveillance-alone-dropping-prophylactic-cranial-irradiation-in-sclc 2026-09-13T13:49:02+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-laa-acquires-j-j-s-laminar-program-marking-j-j-s-exit-from-laa-closure-market 2026-09-13T09:48:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaguar-laa-acquires-j-j-s-laminar-program-marking-j-j-s-exit-from-laa-closure-market 2026-09-13T09:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/indian-patent-office-proposes-overhaul-of-pharma-and-biotech-patent-examination-guidelines 2026-09-13T08:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-patent-office-proposes-overhaul-of-pharma-and-biotech-patent-examination-guidelines 2026-09-13T08:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-targets-500m-biosimilars-revenue-expands-manufacturing-and-launches-oncology-spin-off-funding 2026-09-13T07:10:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-targets-500m-biosimilars-revenue-expands-manufacturing-and-launches-oncology-spin-off-funding 2026-09-13T07:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/ris-rez-cuts-death-risk-54-versus-topotecan-in-relapsed-sclc-first-phase-iii-os-win-for-a-b7-h3-adc 2026-09-13T07:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ris-rez-cuts-death-risk-54-versus-topotecan-in-relapsed-sclc-first-phase-iii-os-win-for-a-b7-h3-adc 2026-09-13T07:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/apr-s-rf-microporation-boosts-minoxidil-skin-deposition-2-4x-in-preclinical-hair-loss-study 2026-09-13T06:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apr-s-rf-microporation-boosts-minoxidil-skin-deposition-2-4x-in-preclinical-hair-loss-study 2026-09-13T06:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/sacituzumab-govitecan-plus-pembrolizumab-misses-primary-endpoints-in-first-line-pd-l1-high-metastatic-nsclc 2026-09-13T04:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sacituzumab-govitecan-plus-pembrolizumab-misses-primary-endpoints-in-first-line-pd-l1-high-metastatic-nsclc 2026-09-13T04:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/ivonescimab-beats-pembrolizumab-on-overall-survival-in-first-line-pd-l1-positive-nsclc-harmoni-2-data-at-wclc-2026 2026-09-13T01:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivonescimab-beats-pembrolizumab-on-overall-survival-in-first-line-pd-l1-positive-nsclc-harmoni-2-data-at-wclc-2026 2026-09-13T01:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/roche-partner-medilink-s-b7-h3-adc-tam-peli-cuts-death-risk-54-in-relapsed-sclc-phase-iii 2026-09-13T01:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-partner-medilink-s-b7-h3-adc-tam-peli-cuts-death-risk-54-in-relapsed-sclc-phase-iii 2026-09-13T01:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/chek2-mutation-drives-third-cancer-in-15-years-as-patient-begins-lifelong-herceptin-for-stage-four-disease 2026-09-12T23:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chek2-mutation-drives-third-cancer-in-15-years-as-patient-begins-lifelong-herceptin-for-stage-four-disease 2026-09-12T23:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/perzeption-wins-nei-phase-i-sbir-grant-to-develop-tablet-based-photostress-recovery-test-for-amd 2026-09-12T22:53:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perzeption-wins-nei-phase-i-sbir-grant-to-develop-tablet-based-photostress-recovery-test-for-amd 2026-09-12T22:53:57+00:00 hourly 0.9 https://trial.medpath.com/news/mebendazole-cancer-claims-outrun-the-evidence-experts-warn-as-johns-hopkins-patent-fuels-viral-posts 2026-09-12T20:49:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mebendazole-cancer-claims-outrun-the-evidence-experts-warn-as-johns-hopkins-patent-fuels-viral-posts 2026-09-12T20:49:08+00:00 hourly 0.9 https://trial.medpath.com/news/cdph-warns-against-happy-hens-organic-shell-eggs-as-salmonella-enteritidis-outbreak-sickens-23-in-california 2026-09-12T20:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdph-warns-against-happy-hens-organic-shell-eggs-as-salmonella-enteritidis-outbreak-sickens-23-in-california 2026-09-12T20:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/opus-genetics-phentolamine-eye-drops-improve-dim-light-vision-in-phase-iii-lynx-1-trial 2026-09-12T18:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opus-genetics-phentolamine-eye-drops-improve-dim-light-vision-in-phase-iii-lynx-1-trial 2026-09-12T18:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/bloating-led-to-stage-4-ovarian-cancer-diagnosis-oncologist-highlights-very-insidious-disease-with-no-screening-test 2026-09-12T18:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bloating-led-to-stage-4-ovarian-cancer-diagnosis-oncologist-highlights-very-insidious-disease-with-no-screening-test 2026-09-12T18:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/sskm-hospital-administers-first-us-approved-alzheimer-s-drug-in-eastern-india 2026-09-12T16:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sskm-hospital-administers-first-us-approved-alzheimer-s-drug-in-eastern-india 2026-09-12T16:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/perioperative-atezolizumab-plus-chemotherapy-more-than-doubles-event-free-survival-in-resectable-stage-ii-iiib-nsclc 2026-09-12T16:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perioperative-atezolizumab-plus-chemotherapy-more-than-doubles-event-free-survival-in-resectable-stage-ii-iiib-nsclc 2026-09-12T16:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/iza-bren-hits-recommended-phase-3-dose-in-egfr-mutated-nsclc-advancing-to-izabright-lung01 2026-09-12T14:12:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iza-bren-hits-recommended-phase-3-dose-in-egfr-mutated-nsclc-advancing-to-izabright-lung01 2026-09-12T14:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/rare-sst-chodl-cortical-neurons-actively-drive-the-transition-into-sleep-nature-study-finds 2026-09-12T12:56:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rare-sst-chodl-cortical-neurons-actively-drive-the-transition-into-sleep-nature-study-finds 2026-09-12T12:56:02+00:00 hourly 0.9 https://trial.medpath.com/news/lonestar-phase-iii-trial-finds-local-consolidative-therapy-adds-no-survival-benefit-after-dual-immunotherapy-in-metastatic-nsclc 2026-09-12T12:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonestar-phase-iii-trial-finds-local-consolidative-therapy-adds-no-survival-benefit-after-dual-immunotherapy-in-metastatic-nsclc 2026-09-12T12:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-tarlatamab-matches-iv-exposure-with-low-grade-toxicity-in-phase-1b-es-sclc-trial 2026-09-12T11:53:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-tarlatamab-matches-iv-exposure-with-low-grade-toxicity-in-phase-1b-es-sclc-trial 2026-09-12T11:53:53+00:00 hourly 0.9 https://trial.medpath.com/news/dellphi-309-extended-interval-tarlatamab-dosing-shows-comparable-activity-in-relapsed-sclc 2026-09-12T11:50:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dellphi-309-extended-interval-tarlatamab-dosing-shows-comparable-activity-in-relapsed-sclc 2026-09-12T11:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-closes-2-8b-ataibeckley-acquisition-adding-rapid-acting-neuroplastogen-bpl-003-for-treatment-resistant-depression 2026-09-12T06:50:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-closes-2-8b-ataibeckley-acquisition-adding-rapid-acting-neuroplastogen-bpl-003-for-treatment-resistant-depression 2026-09-12T06:50:31+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-receives-sec-approval-for-oeris-injection-lasting-up-to-120-hours 2026-09-12T04:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-receives-sec-approval-for-oeris-injection-lasting-up-to-120-hours 2026-09-12T04:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/first-analysis-of-eight-myotis-bat-genomes-links-longevity-to-antiviral-and-cancer-suppressing-immunity 2026-09-12T01:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-analysis-of-eight-myotis-bat-genomes-links-longevity-to-antiviral-and-cancer-suppressing-immunity 2026-09-12T01:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/editas-medicine-targets-2026-patient-dosing-for-in-vivo-crispr-ldl-therapy-edit-401 2026-09-12T01:13:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/editas-medicine-targets-2026-patient-dosing-for-in-vivo-crispr-ldl-therapy-edit-401 2026-09-12T01:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/radiotherapy-plus-immunotherapy-in-oligometastatic-nsclc-review-maps-path-to-individualized-multimodal-care 2026-09-12T00:52:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiotherapy-plus-immunotherapy-in-oligometastatic-nsclc-review-maps-path-to-individualized-multimodal-care 2026-09-12T00:52:24+00:00 hourly 0.9 https://trial.medpath.com/news/hormone-therapy-in-breast-and-prostate-cancer-receptor-degraders-target-treatment-resistance 2026-09-12T00:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hormone-therapy-in-breast-and-prostate-cancer-receptor-degraders-target-treatment-resistance 2026-09-12T00:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/ub-awarded-5-million-to-lead-suny-brain-institute-hub-for-age-related-brain-disorders 2026-09-12T00:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ub-awarded-5-million-to-lead-suny-brain-institute-hub-for-age-related-brain-disorders 2026-09-12T00:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-scholar-rock-s-isembyld-first-muscle-targeted-therapy-for-spinal-muscular-atrophy 2026-09-11T23:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-scholar-rock-s-isembyld-first-muscle-targeted-therapy-for-spinal-muscular-atrophy 2026-09-11T23:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/dietary-supplement-innovation-act-targets-fda-s-drug-preclusion-clause 2026-09-11T21:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dietary-supplement-innovation-act-targets-fda-s-drug-preclusion-clause 2026-09-11T21:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-etcamah-misses-primary-pfs-endpoint-in-phase-iii-serena-4-first-line-breast-cancer-trial 2026-09-11T21:00:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-etcamah-misses-primary-pfs-endpoint-in-phase-iii-serena-4-first-line-breast-cancer-trial 2026-09-11T21:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/pennsylvania-reports-four-measles-breakthrough-cases-in-fully-vaccinated-residents-amid-largest-outbreak-in-30-years 2026-09-11T20:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pennsylvania-reports-four-measles-breakthrough-cases-in-fully-vaccinated-residents-amid-largest-outbreak-in-30-years 2026-09-11T20:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-usa-pickleball-launch-serve-up-protection-campaign-to-boost-awareness-of-protein-based-nuvaxovid-covid-19-vaccine 2026-09-11T20:49:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-and-usa-pickleball-launch-serve-up-protection-campaign-to-boost-awareness-of-protein-based-nuvaxovid-covid-19-vaccine 2026-09-11T20:49:02+00:00 hourly 0.9 https://trial.medpath.com/news/entrectinib-safety-signals-in-nsclc-replicated-across-faers-and-jader-with-early-neurologic-cardiac-and-renal-events 2026-09-11T19:48:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entrectinib-safety-signals-in-nsclc-replicated-across-faers-and-jader-with-early-neurologic-cardiac-and-renal-events 2026-09-11T19:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-pharming-s-joenja-as-first-treatment-for-children-aged-4-to-11-with-apds 2026-09-11T18:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-pharming-s-joenja-as-first-treatment-for-children-aged-4-to-11-with-apds 2026-09-11T18:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-nutromics-wearable-vancomycin-monitoring-patch 2026-09-11T17:48:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-nutromics-wearable-vancomycin-monitoring-patch 2026-09-11T17:48:42+00:00 hourly 0.9 https://trial.medpath.com/news/glycocalyx-edited-stem-cell-infusion-cuts-fragility-fractures-by-94-in-first-in-human-osteoporosis-trial 2026-09-11T17:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glycocalyx-edited-stem-cell-infusion-cuts-fragility-fractures-by-94-in-first-in-human-osteoporosis-trial 2026-09-11T17:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/allogenetics-raises-eur3-8m-pre-series-a-to-advance-ex-vivo-gene-therapy-for-rejection-resistant-donor-lungs 2026-09-11T16:50:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogenetics-raises-eur3-8m-pre-series-a-to-advance-ex-vivo-gene-therapy-for-rejection-resistant-donor-lungs 2026-09-11T16:50:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-of-exelixis-zanzalintinib-plus-tecentriq-in-metastatic-colorectal-cancer-to-march-2027 2026-09-11T16:48:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-extends-review-of-exelixis-zanzalintinib-plus-tecentriq-in-metastatic-colorectal-cancer-to-march-2027 2026-09-11T16:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-holds-pharma-r-d-lead-as-obesity-pipeline-swells-30-7-and-rare-disease-share-rises 2026-09-11T15:55:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-holds-pharma-r-d-lead-as-obesity-pipeline-swells-30-7-and-rare-disease-share-rises 2026-09-11T15:55:53+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-hengrui-s-oral-tpo-ra-hetrombopag-for-thrombocytopenia 2026-09-11T15:55:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-hengrui-s-oral-tpo-ra-hetrombopag-for-thrombocytopenia 2026-09-11T15:55:38+00:00 hourly 0.9 https://trial.medpath.com/news/efemp1-p-arg140trp-variant-identified-as-cause-of-newly-recognized-late-onset-retinal-degeneration 2026-09-11T15:55:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efemp1-p-arg140trp-variant-identified-as-cause-of-newly-recognized-late-onset-retinal-degeneration 2026-09-11T15:55:16+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-capture-dna-strands-zipping-together-offering-new-clues-to-cancer-and-genome-organization 2026-09-11T15:55:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-capture-dna-strands-zipping-together-offering-new-clues-to-cancer-and-genome-organization 2026-09-11T15:55:12+00:00 hourly 0.9 https://trial.medpath.com/news/adhd-linked-to-nearly-50-higher-odds-of-gastrointestinal-symptoms-in-1-9-million-person-review 2026-09-11T15:55:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adhd-linked-to-nearly-50-higher-odds-of-gastrointestinal-symptoms-in-1-9-million-person-review 2026-09-11T15:55:03+00:00 hourly 0.9 https://trial.medpath.com/news/alltrna-doses-first-trna-therapy-in-humans-as-ap003-phase-1-begins-in-australia 2026-09-11T13:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alltrna-doses-first-trna-therapy-in-humans-as-ap003-phase-1-begins-in-australia 2026-09-11T13:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/hiti-genome-editing-repairs-native-otc-gene-in-liver-cells-offering-mutation-agnostic-strategy-for-pediatric-gene-therapy 2026-09-11T13:49:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiti-genome-editing-repairs-native-otc-gene-in-liver-cells-offering-mutation-agnostic-strategy-for-pediatric-gene-therapy 2026-09-11T13:49:08+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-therapy-reshapes-mutant-cell-selection-in-normal-esophagus-sanger-led-study-finds 2026-09-11T12:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-therapy-reshapes-mutant-cell-selection-in-normal-esophagus-sanger-led-study-finds 2026-09-11T12:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-wide-study-identifies-24-common-prescribing-cascades-driving-drug-harm-in-older-adults 2026-09-11T12:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ontario-wide-study-identifies-24-common-prescribing-cascades-driving-drug-harm-in-older-adults 2026-09-11T12:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-linked-ocular-surface-disease-affects-nearly-one-third-of-atopic-dermatitis-patients-but-rarely-forces-discontinuation 2026-09-11T12:49:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-linked-ocular-surface-disease-affects-nearly-one-third-of-atopic-dermatitis-patients-but-rarely-forces-discontinuation 2026-09-11T12:49:15+00:00 hourly 0.9 https://trial.medpath.com/news/step-volume-or-step-pace-large-cohort-study-finds-both-walking-strategies-lower-mortality-risk 2026-09-11T12:48:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/step-volume-or-step-pace-large-cohort-study-finds-both-walking-strategies-lower-mortality-risk 2026-09-11T12:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-secures-zegfrovy-rights-in-up-to-1-5b-deal 2026-09-11T12:17:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-secures-zegfrovy-rights-in-up-to-1-5b-deal 2026-09-11T12:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/owkin-licenses-k-pro-ai-scientist-and-mosaic-patient-data-to-servier-for-oncology-research 2026-09-11T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/owkin-licenses-k-pro-ai-scientist-and-mosaic-patient-data-to-servier-for-oncology-research 2026-09-11T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/yuhan-wins-u-s-patent-for-preclinical-lox-inhibitor-candidate-targeting-multi-organ-fibrosis 2026-09-11T10:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yuhan-wins-u-s-patent-for-preclinical-lox-inhibitor-candidate-targeting-multi-organ-fibrosis 2026-09-11T10:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/korea-issues-early-influenza-advisory-as-cases-hit-twice-the-epidemic-threshold 2026-09-11T10:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korea-issues-early-influenza-advisory-as-cases-hit-twice-the-epidemic-threshold 2026-09-11T10:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/padeliporfin-vtp-converts-inoperable-pancreatic-tumors-to-resectable-in-early-phase-1-data 2026-09-11T10:48:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/padeliporfin-vtp-converts-inoperable-pancreatic-tumors-to-resectable-in-early-phase-1-data 2026-09-11T10:48:33+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-commits-eur1-million-to-fund-academic-cancer-trials-targeting-treatment-de-escalation-and-care-optimization 2026-09-11T08:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esmo-commits-eur1-million-to-fund-academic-cancer-trials-targeting-treatment-de-escalation-and-care-optimization 2026-09-11T08:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-lundbeck-s-anti-acth-antibody-asedebart-for-endogenous-cushing-s-syndrome 2026-09-11T08:27:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-lundbeck-s-anti-acth-antibody-asedebart-for-endogenous-cushing-s-syndrome 2026-09-11T08:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/pelacarsen-and-ziltivekimab-fail-late-stage-trials-ending-the-genetics-is-undefeated-era-in-cardiovascular-drug-development 2026-09-11T06:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelacarsen-and-ziltivekimab-fail-late-stage-trials-ending-the-genetics-is-undefeated-era-in-cardiovascular-drug-development 2026-09-11T06:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-accepts-ncx-470-nda-for-review-in-open-angle-glaucoma-and-ocular-hypertension 2026-09-11T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-accepts-ncx-470-nda-for-review-in-open-angle-glaucoma-and-ocular-hypertension 2026-09-11T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/time100-health-forum-experts-point-to-vaccines-immunotherapy-and-early-detection-as-path-to-curing-cancer 2026-09-11T03:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/time100-health-forum-experts-point-to-vaccines-immunotherapy-and-early-detection-as-path-to-curing-cancer 2026-09-11T03:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/genencell-covid-19-drug-es16001-approved-for-phase-2-3-without-liver-injury-endpoint-despite-phase-1-enzyme-elevations 2026-09-11T03:48:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genencell-covid-19-drug-es16001-approved-for-phase-2-3-without-liver-injury-endpoint-despite-phase-1-enzyme-elevations 2026-09-11T03:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/uab-chemists-advance-targeted-alpha-therapy-with-astatine-211-and-theragnostic-nanomaterials 2026-09-11T02:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uab-chemists-advance-targeted-alpha-therapy-with-astatine-211-and-theragnostic-nanomaterials 2026-09-11T02:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/mitsui-signs-service-agreement-with-oncoshot-to-build-asia-us-oncology-real-world-data-network 2026-09-11T02:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitsui-signs-service-agreement-with-oncoshot-to-build-asia-us-oncology-real-world-data-network 2026-09-11T02:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-refocuses-eftilagimod-alfa-development-on-hnscc-with-cps-1-and-neoadjuvant-soft-tissue-sarcoma 2026-09-11T02:17:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-refocuses-eftilagimod-alfa-development-on-hnscc-with-cps-1-and-neoadjuvant-soft-tissue-sarcoma 2026-09-11T02:17:53+00:00 hourly 0.9 https://trial.medpath.com/news/lancet-publication-details-phase-3-win-for-csl-seqirus-s-triple-enhanced-aqivc-influenza-vaccine-in-older-adults 2026-09-11T01:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lancet-publication-details-phase-3-win-for-csl-seqirus-s-triple-enhanced-aqivc-influenza-vaccine-in-older-adults 2026-09-11T01:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-wins-south-korean-phase-2-ind-approval-for-covid-19-mrna-vaccine-gc4006a 2026-09-11T00:16:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-biopharma-wins-south-korean-phase-2-ind-approval-for-covid-19-mrna-vaccine-gc4006a 2026-09-11T00:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-zanvastro-first-disease-modifying-therapy-for-alexander-disease 2026-09-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-zanvastro-first-disease-modifying-therapy-for-alexander-disease 2026-09-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-il-2-discovery-50-years-on-recognized-as-foundation-of-modern-cancer-immunotherapy 2026-09-10T22:54:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-il-2-discovery-50-years-on-recognized-as-foundation-of-modern-cancer-immunotherapy 2026-09-10T22:54:37+00:00 hourly 0.9 https://trial.medpath.com/news/shoulder-innovations-wins-fda-510-k-clearance-for-n-22-humeral-head-launches-titanium-implant-for-metal-sensitive-patients 2026-09-10T21:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shoulder-innovations-wins-fda-510-k-clearance-for-n-22-humeral-head-launches-titanium-implant-for-metal-sensitive-patients 2026-09-10T21:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-not-chemotherapy-drives-hair-repigmentation-in-thoracic-cancer-patients 2026-09-10T19:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-not-chemotherapy-drives-hair-repigmentation-in-thoracic-cancer-patients 2026-09-10T19:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ide-approval-to-ciliatech-for-intercil-uveal-spacer-glaucoma-feasibility-study 2026-09-10T19:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-ide-approval-to-ciliatech-for-intercil-uveal-spacer-glaucoma-feasibility-study 2026-09-10T19:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/salk-team-maps-how-chronic-interferon-ii-drives-immunosuppression-and-anti-pd1-resistance-in-melanoma 2026-09-10T19:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salk-team-maps-how-chronic-interferon-ii-drives-immunosuppression-and-anti-pd1-resistance-in-melanoma 2026-09-10T19:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-cu-anschutz-trial-of-dual-target-car-t-cell-therapy-for-advanced-colorectal-cancer 2026-09-10T19:24:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-cu-anschutz-trial-of-dual-target-car-t-cell-therapy-for-advanced-colorectal-cancer 2026-09-10T19:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-quantum-biopharma-s-ind-for-lucid-ms-a-first-in-class-pad2-inhibitor-in-phase-2-multiple-sclerosis-trial 2026-09-10T19:02:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-quantum-biopharma-s-ind-for-lucid-ms-a-first-in-class-pad2-inhibitor-in-phase-2-multiple-sclerosis-trial 2026-09-10T19:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-aligns-with-rocket-pharmaceuticals-on-12-patient-pivotal-phase-2-design-for-danon-disease-gene-therapy-rp-a501 2026-09-10T18:51:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-aligns-with-rocket-pharmaceuticals-on-12-patient-pivotal-phase-2-design-for-danon-disease-gene-therapy-rp-a501 2026-09-10T18:51:59+00:00 hourly 0.9 https://trial.medpath.com/news/tennor-s-rifaquizinone-achieves-100-success-in-early-periprosthetic-joint-infection-phase-iib-trial-underway 2026-09-10T18:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tennor-s-rifaquizinone-achieves-100-success-in-early-periprosthetic-joint-infection-phase-iib-trial-underway 2026-09-10T18:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/bgi-group-unveils-digital-life-twin-framework-and-multimodal-brain-on-chip-at-2026-global-launch 2026-09-10T17:49:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bgi-group-unveils-digital-life-twin-framework-and-multimodal-brain-on-chip-at-2026-global-launch 2026-09-10T17:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/graph-ai-raises-13-3m-series-a-to-scale-ai-native-pharmacovigilance-platform 2026-09-10T17:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/graph-ai-raises-13-3m-series-a-to-scale-ai-native-pharmacovigilance-platform 2026-09-10T17:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/penn-medicine-receives-50-million-gift-to-fund-early-stage-cancer-autoimmune-and-infectious-disease-research 2026-09-10T17:48:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-medicine-receives-50-million-gift-to-fund-early-stage-cancer-autoimmune-and-infectious-disease-research 2026-09-10T17:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-unveils-next-generation-telomere-targeting-prodrugs-at-irt-2026 2026-09-10T17:48:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-unveils-next-generation-telomere-targeting-prodrugs-at-irt-2026 2026-09-10T17:48:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-oncolytic-virus 2026-09-10T17:39:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-oncolytic-virus 2026-09-10T17:39:23+00:00 hourly 0.9 https://trial.medpath.com/news/columbia-university-irving-medical-center-and-aws-partner-to-accelerate-ai-driven-biomarker-and-diagnostic-discovery 2026-09-10T16:49:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/columbia-university-irving-medical-center-and-aws-partner-to-accelerate-ai-driven-biomarker-and-diagnostic-discovery 2026-09-10T16:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/biolife-secures-u-s-patent-for-effervescent-oral-peptide-delivery-technology-covering-glp-1-receptor-agonists 2026-09-10T16:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolife-secures-u-s-patent-for-effervescent-oral-peptide-delivery-technology-covering-glp-1-receptor-agonists 2026-09-10T16:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/bmj-investigation-half-of-england-s-icbs-impose-minimum-waits-of-up-to-16-weeks-for-elective-surgery 2026-09-10T16:49:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bmj-investigation-half-of-england-s-icbs-impose-minimum-waits-of-up-to-16-weeks-for-elective-surgery 2026-09-10T16:49:06+00:00 hourly 0.9 https://trial.medpath.com/news/nighttime-light-exposure-linked-to-cardiac-remodelling-in-11000-person-uk-biobank-study 2026-09-10T16:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nighttime-light-exposure-linked-to-cardiac-remodelling-in-11000-person-uk-biobank-study 2026-09-10T16:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/obviohealth-and-sprim-pro-launch-integrated-digital-patient-monitoring-solution-for-high-risk-therapies 2026-09-10T16:48:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obviohealth-and-sprim-pro-launch-integrated-digital-patient-monitoring-solution-for-high-risk-therapies 2026-09-10T16:48:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-moderna-s-mrna-influenza-vaccine 2026-09-10T16:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-moderna-s-mrna-influenza-vaccine 2026-09-10T16:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/dellphi-305-durvalumab-plus-tarlatamab-hits-overall-survival-in-first-line-es-sclc-maintenance 2026-09-10T16:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dellphi-305-durvalumab-plus-tarlatamab-hits-overall-survival-in-first-line-es-sclc-maintenance 2026-09-10T16:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-partial-clinical-hold-on-biohaven-s-epilepsy-candidate-opakalim-pausing-new-enrollment-in-pivotal-program 2026-09-10T14:54:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-partial-clinical-hold-on-biohaven-s-epilepsy-candidate-opakalim-pausing-new-enrollment-in-pivotal-program 2026-09-10T14:54:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-prelude-therapeutics-first-in-class-oral-kat6a-degrader-prt13722-in-hr-her2-breast-cancer 2026-09-10T14:50:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-prelude-therapeutics-first-in-class-oral-kat6a-degrader-prt13722-in-hr-her2-breast-cancer 2026-09-10T14:50:38+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-survey-all-responding-cancer-centers-report-at-least-one-anticancer-drug-shortage-as-ifosfamide-gaps-hit-94 2026-09-10T14:50:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-survey-all-responding-cancer-centers-report-at-least-one-anticancer-drug-shortage-as-ifosfamide-gaps-hit-94 2026-09-10T14:50:35+00:00 hourly 0.9 https://trial.medpath.com/news/eib-and-hera-commit-eur30m-to-ethris-for-broad-spectrum-nasal-antiviral-mrna 2026-09-10T14:49:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eib-and-hera-commit-eur30m-to-ethris-for-broad-spectrum-nasal-antiviral-mrna 2026-09-10T14:49:49+00:00 hourly 0.9 https://trial.medpath.com/news/headlands-research-opens-de-novo-grand-rapids-site-to-meet-rising-rheumatology-trial-demand 2026-09-10T14:49:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/headlands-research-opens-de-novo-grand-rapids-site-to-meet-rising-rheumatology-trial-demand 2026-09-10T14:49:38+00:00 hourly 0.9 https://trial.medpath.com/news/our-future-health-cohort-tops-1-9-million-participants-mapping-disease-patterns-across-the-uk 2026-09-10T14:49:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/our-future-health-cohort-tops-1-9-million-participants-mapping-disease-patterns-across-the-uk 2026-09-10T14:49:33+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-26m-to-advance-ri-ctr-for-third-five-year-phase-of-clinical-and-translational-research 2026-09-10T14:49:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-26m-to-advance-ri-ctr-for-third-five-year-phase-of-clinical-and-translational-research 2026-09-10T14:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-launches-early-life-exposure-research-center-to-track-9-11-health-effects-in-youngest-survivors 2026-09-10T14:49:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-launches-early-life-exposure-research-center-to-track-9-11-health-effects-in-youngest-survivors 2026-09-10T14:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/alteogen-licenses-alt-b4-to-novartis-in-deal-worth-up-to-3-2-billion 2026-09-10T14:29:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alteogen-licenses-alt-b4-to-novartis-in-deal-worth-up-to-3-2-billion 2026-09-10T14:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-atogepant-hits-primary-and-all-eight-secondary-endpoints-in-phase-iii-menstrual-migraine-trial 2026-09-10T13:54:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-atogepant-hits-primary-and-all-eight-secondary-endpoints-in-phase-iii-menstrual-migraine-trial 2026-09-10T13:54:10+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-s-zipalertinib-plus-chemotherapy-hits-primary-endpoint-in-phase-3-rezilient3-interim-data-headed-to-wclc-presidential-symposium 2026-09-10T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullinan-s-zipalertinib-plus-chemotherapy-hits-primary-endpoint-in-phase-3-rezilient3-interim-data-headed-to-wclc-presidential-symposium 2026-09-10T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/teitur-trophics-first-in-class-peptide-tt-p34-clears-phase-i-in-parkinson-s-confirming-brain-exposure 2026-09-10T12:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teitur-trophics-first-in-class-peptide-tt-p34-clears-phase-i-in-parkinson-s-confirming-brain-exposure 2026-09-10T12:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/icecure-medical-wins-nmpa-approval-to-market-prosense-cryoablation-system-in-china 2026-09-10T12:00:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icecure-medical-wins-nmpa-approval-to-market-prosense-cryoablation-system-in-china 2026-09-10T12:00:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-partial-clinical-hold-halts-new-enrollment-in-sk-biopharmaceuticals-opacalim-rise2-epilepsy-trial 2026-09-10T11:52:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-partial-clinical-hold-halts-new-enrollment-in-sk-biopharmaceuticals-opacalim-rise2-epilepsy-trial 2026-09-10T11:52:12+00:00 hourly 0.9 https://trial.medpath.com/news/matterhorn-final-os-perioperative-durvalumab-plus-flot-cuts-death-risk-22-in-resectable-gastric-gej-cancer 2026-09-10T11:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matterhorn-final-os-perioperative-durvalumab-plus-flot-cuts-death-risk-22-in-resectable-gastric-gej-cancer 2026-09-10T11:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/cervomed-s-neflamapimod-phase-2a-biomarker-data-in-nfvppa-selected-for-late-breaking-isftd-presentation 2026-09-10T11:43:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cervomed-s-neflamapimod-phase-2a-biomarker-data-in-nfvppa-selected-for-late-breaking-isftd-presentation 2026-09-10T11:43:23+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-s-ino-3107-nears-oct-30-fda-decision-for-recurrent-respiratory-papillomatosis 2026-09-10T11:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-s-ino-3107-nears-oct-30-fda-decision-for-recurrent-respiratory-papillomatosis 2026-09-10T11:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/adaura-update-adjuvant-tagrisso-cuts-death-risk-48-at-eight-years-in-resected-egfr-mutated-nsclc 2026-09-10T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaura-update-adjuvant-tagrisso-cuts-death-risk-48-at-eight-years-in-resected-egfr-mutated-nsclc 2026-09-10T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tevard-biosciences-publishes-preclinical-data-on-engineered-suppressor-trna-gene-therapy-for-duchenne-muscular-dystrophy 2026-09-10T10:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tevard-biosciences-publishes-preclinical-data-on-engineered-suppressor-trna-gene-therapy-for-duchenne-muscular-dystrophy 2026-09-10T10:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/ondine-s-lantern-phase-iii-trial-hits-primary-endpoint-with-41-reduction-in-surgical-site-infections 2026-09-10T10:41:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ondine-s-lantern-phase-iii-trial-hits-primary-endpoint-with-41-reduction-in-surgical-site-infections 2026-09-10T10:41:57+00:00 hourly 0.9 https://trial.medpath.com/news/wegovy-becomes-first-glp-1-receptor-agonist-approved-in-china-for-mash-with-moderate-to-severe-fibrosis 2026-09-10T09:45:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wegovy-becomes-first-glp-1-receptor-agonist-approved-in-china-for-mash-with-moderate-to-severe-fibrosis 2026-09-10T09:45:22+00:00 hourly 0.9 https://trial.medpath.com/news/merck-targets-70b-pipeline-opportunity-as-keytruda-loss-of-exclusivity-nears-in-2028 2026-09-10T08:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-targets-70b-pipeline-opportunity-as-keytruda-loss-of-exclusivity-nears-in-2028 2026-09-10T08:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/four-japanese-researchers-win-lasker-awards-for-sleep-science-and-hemophilia-drug-hemlibra 2026-09-10T08:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-japanese-researchers-win-lasker-awards-for-sleep-science-and-hemophilia-drug-hemlibra 2026-09-10T08:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/palvella-s-qtorin-nda-filed-for-rare-disease-with-exclusivity-through-2040s 2026-09-10T08:38:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palvella-s-qtorin-nda-filed-for-rare-disease-with-exclusivity-through-2040s 2026-09-10T08:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-bayer-s-hyrnuo-sevabertinib-as-first-line-therapy-for-her2-mutated-nsclc 2026-09-10T07:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-bayer-s-hyrnuo-sevabertinib-as-first-line-therapy-for-her2-mutated-nsclc 2026-09-10T07:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/ascelia-pharma-completes-fda-type-a-meeting-on-orviglance-nda-following-complete-response-letter 2026-09-10T06:49:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascelia-pharma-completes-fda-type-a-meeting-on-orviglance-nda-following-complete-response-letter 2026-09-10T06:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/india-clarifies-patent-boundaries-for-life-sciences-in-court-driven-guidelines 2026-09-10T06:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-clarifies-patent-boundaries-for-life-sciences-in-court-driven-guidelines 2026-09-10T06:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-roche-s-enspryng-for-mogad-with-decision-due-january-2027 2026-09-10T05:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-roche-s-enspryng-for-mogad-with-decision-due-january-2027 2026-09-10T05:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-daraxonrasib-rasonque-first-in-class-ras-on-inhibitor-for-metastatic-pancreatic-cancer 2026-09-10T04:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-daraxonrasib-rasonque-first-in-class-ras-on-inhibitor-for-metastatic-pancreatic-cancer 2026-09-10T04:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/methylglyoxal-stress-drives-immune-suppression-and-immunotherapy-resistance-in-triple-negative-breast-cancer 2026-09-10T03:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/methylglyoxal-stress-drives-immune-suppression-and-immunotherapy-resistance-in-triple-negative-breast-cancer 2026-09-10T03:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-imdelltra-plus-imfinzi-hits-primary-endpoint-in-first-line-es-sclc-maintenance 2026-09-10T01:18:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-imdelltra-plus-imfinzi-hits-primary-endpoint-in-first-line-es-sclc-maintenance 2026-09-10T01:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-doses-first-patient-in-genesis-ipf-3-the-first-phase-iii-trial-of-a-generative-ai-discovered-drug 2026-09-10T00:59:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-doses-first-patient-in-genesis-ipf-3-the-first-phase-iii-trial-of-a-generative-ai-discovered-drug 2026-09-10T00:59:02+00:00 hourly 0.9 https://trial.medpath.com/news/beeline-medicines-afimetoran-hits-primary-endpoint-in-global-phase-2-sle-trial-advancing-to-pivotal-development 2026-09-10T00:50:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beeline-medicines-afimetoran-hits-primary-endpoint-in-global-phase-2-sle-trial-advancing-to-pivotal-development 2026-09-10T00:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/25000-year-old-teeth-reveal-earliest-known-evidence-of-human-drug-use 2026-09-10T00:49:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/25000-year-old-teeth-reveal-earliest-known-evidence-of-human-drug-use 2026-09-10T00:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-s-tslp-antibody-hbm9378-delivers-24-week-asthma-control-after-single-dose-supporting-twice-yearly-regimen 2026-09-10T00:27:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-s-tslp-antibody-hbm9378-delivers-24-week-asthma-control-after-single-dose-supporting-twice-yearly-regimen 2026-09-10T00:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-abbott-s-dual-energy-tactiflex-duo-ablation-catheter-for-complex-atrial-fibrillation 2026-09-10T00:15:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-abbott-s-dual-energy-tactiflex-duo-ablation-catheter-for-complex-atrial-fibrillation 2026-09-10T00:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/stamina-trial-supervised-exercise-and-diet-program-cuts-quality-of-life-decline-by-a-third-in-men-on-androgen-deprivation-therapy 2026-09-09T23:48:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stamina-trial-supervised-exercise-and-diet-program-cuts-quality-of-life-decline-by-a-third-in-men-on-androgen-deprivation-therapy 2026-09-09T23:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/seismic-pharmaceuticals-commences-global-phase-3-trial-of-istaroxime-for-cardiogenic-shock 2026-09-09T22:59:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seismic-pharmaceuticals-commences-global-phase-3-trial-of-istaroxime-for-cardiogenic-shock 2026-09-09T22:59:02+00:00 hourly 0.9 https://trial.medpath.com/news/beren-therapeutics-and-genedx-launch-test-for-npc-to-accelerate-diagnosis-of-niemann-pick-disease-type-c 2026-09-09T22:58:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beren-therapeutics-and-genedx-launch-test-for-npc-to-accelerate-diagnosis-of-niemann-pick-disease-type-c 2026-09-09T22:58:36+00:00 hourly 0.9 https://trial.medpath.com/news/cellipont-and-xiogenix-white-paper-shows-automated-fill-finish-maintains-cell-viability-across-17-fold-scale-up 2026-09-09T22:55:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellipont-and-xiogenix-white-paper-shows-automated-fill-finish-maintains-cell-viability-across-17-fold-scale-up 2026-09-09T22:55:25+00:00 hourly 0.9 https://trial.medpath.com/news/apple-health-app-users-to-order-quest-diagnostics-biomarker-lab-panels-directly-in-app 2026-09-09T22:55:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apple-health-app-users-to-order-quest-diagnostics-biomarker-lab-panels-directly-in-app 2026-09-09T22:55:12+00:00 hourly 0.9 https://trial.medpath.com/news/navion-neurosciences-closes-10-8m-seed-financing-to-advance-precision-sodium-channel-medicines-for-epilepsy-and-neuropathic-pain 2026-09-09T22:54:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navion-neurosciences-closes-10-8m-seed-financing-to-advance-precision-sodium-channel-medicines-for-epilepsy-and-neuropathic-pain 2026-09-09T22:54:47+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-working-on-more-drug-pricing-deals-oz-says 2026-09-09T22:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-working-on-more-drug-pricing-deals-oz-says 2026-09-09T22:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-orzeyful-oveporexton-first-orexin-agonist-for-narcolepsy-type-1 2026-09-09T21:58:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-orzeyful-oveporexton-first-orexin-agonist-for-narcolepsy-type-1 2026-09-09T21:58:48+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-s-disc-3405-cuts-phlebotomy-burden-in-phase-2-polycythemia-vera-trial 2026-09-09T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disc-medicine-s-disc-3405-cuts-phlebotomy-burden-in-phase-2-polycythemia-vera-trial 2026-09-09T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/crossbow-therapeutics-doses-first-patient-in-phase-1-trial-of-first-in-class-t-cell-engager-cbx-663 2026-09-09T20:51:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crossbow-therapeutics-doses-first-patient-in-phase-1-trial-of-first-in-class-t-cell-engager-cbx-663 2026-09-09T20:51:05+00:00 hourly 0.9 https://trial.medpath.com/news/1cbio-licenses-preclinical-parp1-inhibitor-oc-3-to-lee-s-pharm-for-greater-china-and-southeast-asia-in-deal-worth-up-to-27-million 2026-09-09T20:50:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/1cbio-licenses-preclinical-parp1-inhibitor-oc-3-to-lee-s-pharm-for-greater-china-and-southeast-asia-in-deal-worth-up-to-27-million 2026-09-09T20:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/twostep-therapeutics-raises-62-5m-series-a-and-wins-fda-ind-clearance-for-first-in-class-multi-specific-peptide-drug-conjugate-ts-104 2026-09-09T20:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/twostep-therapeutics-raises-62-5m-series-a-and-wins-fda-ind-clearance-for-first-in-class-multi-specific-peptide-drug-conjugate-ts-104 2026-09-09T20:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/bangladesh-measles-deaths-surpass-1000-as-vaccination-drive-falls-short-of-herd-immunity 2026-09-09T20:50:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bangladesh-measles-deaths-surpass-1000-as-vaccination-drive-falls-short-of-herd-immunity 2026-09-09T20:50:07+00:00 hourly 0.9 https://trial.medpath.com/news/fi-recalls-two-dog-supplement-lots-over-salmonella-contamination-risk 2026-09-09T20:50:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fi-recalls-two-dog-supplement-lots-over-salmonella-contamination-risk 2026-09-09T20:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/parabolus-medicines-zolocatetide-posts-74-response-rate-in-desmoid-tumors-targeting-the-undruggable-beta-catenin-tcf-complex 2026-09-09T20:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parabolus-medicines-zolocatetide-posts-74-response-rate-in-desmoid-tumors-targeting-the-undruggable-beta-catenin-tcf-complex 2026-09-09T20:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/apple-s-revamped-health-app-adds-readiness-score-health-age-and-longevity-tracking 2026-09-09T20:49:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apple-s-revamped-health-app-adds-readiness-score-health-age-and-longevity-tracking 2026-09-09T20:49:59+00:00 hourly 0.9 https://trial.medpath.com/news/transcenta-licenses-hicb-continuous-bioprocessing-platform-to-wuxi-biologics-in-strategic-cmc-collaboration 2026-09-09T20:46:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcenta-licenses-hicb-continuous-bioprocessing-platform-to-wuxi-biologics-in-strategic-cmc-collaboration 2026-09-09T20:46:47+00:00 hourly 0.9 https://trial.medpath.com/news/brainomix-ai-imaging-detects-significant-antifibrotic-effects-of-taladegib-in-phase-2a-ipf-trial 2026-09-09T20:19:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainomix-ai-imaging-detects-significant-antifibrotic-effects-of-taladegib-in-phase-2a-ipf-trial 2026-09-09T20:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/sars-cov-2-infection-linked-to-16-lower-risk-of-type-1-diabetes-in-under-30s-danish-registry-study-finds 2026-09-09T19:51:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sars-cov-2-infection-linked-to-16-lower-risk-of-type-1-diabetes-in-under-30s-danish-registry-study-finds 2026-09-09T19:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/two-independent-teams-converge-on-pla2g2d-as-a-novel-immune-checkpoint-to-overcome-anti-pd-1-resistance 2026-09-09T19:51:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-independent-teams-converge-on-pla2g2d-as-a-novel-immune-checkpoint-to-overcome-anti-pd-1-resistance 2026-09-09T19:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/seaport-therapeutics-reports-positive-phase-1-topline-results-from-driving-simulation-study 2026-09-09T19:51:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seaport-therapeutics-reports-positive-phase-1-topline-results-from-driving-simulation-study 2026-09-09T19:51:20+00:00 hourly 0.9 https://trial.medpath.com/news/large-echo-cohort-finds-no-link-between-prenatal-organophosphate-exposure-and-autism-related-traits 2026-09-09T19:50:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-echo-cohort-finds-no-link-between-prenatal-organophosphate-exposure-and-autism-related-traits 2026-09-09T19:50:55+00:00 hourly 0.9 https://trial.medpath.com/news/judge-rules-sandoz-generic-would-infringe-j-j-unit-patents 2026-09-09T19:27:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/judge-rules-sandoz-generic-would-infringe-j-j-unit-patents 2026-09-09T19:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/idsa-updates-guidance-for-managing-resistant-gram-negative-infections 2026-09-09T18:45:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idsa-updates-guidance-for-managing-resistant-gram-negative-infections 2026-09-09T18:45:33+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-and-windward-bio-report-positive-phase-2-interim-data-for-twice-yearly-asthma-antibody-skb378-win378 2026-09-09T18:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-biotech-and-windward-bio-report-positive-phase-2-interim-data-for-twice-yearly-asthma-antibody-skb378-win378 2026-09-09T18:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/china-nmpa-clears-innocare-s-bispecific-adc-icp-b381-for-clinical-trials 2026-09-09T18:15:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-nmpa-clears-innocare-s-bispecific-adc-icp-b381-for-clinical-trials 2026-09-09T18:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/sernova-and-seraxis-merge-to-form-betanova-a-type-1-diabetes-cell-replacement-biotech 2026-09-09T18:12:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sernova-and-seraxis-merge-to-form-betanova-a-type-1-diabetes-cell-replacement-biotech 2026-09-09T18:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-sobi-s-pacritinib-for-vexas-syndrome 2026-09-09T18:00:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-sobi-s-pacritinib-for-vexas-syndrome 2026-09-09T18:00:35+00:00 hourly 0.9 https://trial.medpath.com/news/trialbee-launches-ai-pre-screening-agent-in-honey-platform-to-speed-trial-enrollment 2026-09-09T17:50:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trialbee-launches-ai-pre-screening-agent-in-honey-platform-to-speed-trial-enrollment 2026-09-09T17:50:47+00:00 hourly 0.9 https://trial.medpath.com/news/rezera-s-oral-nlrp3-inhibitor-ruvonoflast-hits-primary-inflammation-endpoint-in-phase-2-resolve-1-phase-3-pad-trial-planned-for-2027 2026-09-09T17:50:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezera-s-oral-nlrp3-inhibitor-ruvonoflast-hits-primary-inflammation-endpoint-in-phase-2-resolve-1-phase-3-pad-trial-planned-for-2027 2026-09-09T17:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-doses-first-patient-in-pnoc035-phase-2-trial-of-paxalisib-plus-gemcitabine-for-recurrent-pediatric-at-rt 2026-09-09T17:49:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-therapeutics-doses-first-patient-in-pnoc035-phase-2-trial-of-paxalisib-plus-gemcitabine-for-recurrent-pediatric-at-rt 2026-09-09T17:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/three-chugai-researchers-behind-hemlibra-discovery-receive-lasker-debakey-clinical-medical-research-award 2026-09-09T17:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-chugai-researchers-behind-hemlibra-discovery-receive-lasker-debakey-clinical-medical-research-award 2026-09-09T17:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/encoded-therapeutics-raises-275m-series-f-to-push-etx101-gene-therapy-through-pivotal-dravet-syndrome-development 2026-09-09T17:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/encoded-therapeutics-raises-275m-series-f-to-push-etx101-gene-therapy-through-pivotal-dravet-syndrome-development 2026-09-09T17:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-and-genentech-terminate-phase-ii-autogene-cevumeran-trial-in-resected-colorectal-cancer-after-os-imbalance-favors-control 2026-09-09T17:41:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-and-genentech-terminate-phase-ii-autogene-cevumeran-trial-in-resected-colorectal-cancer-after-os-imbalance-favors-control 2026-09-09T17:41:38+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-and-servier-dose-first-patient-in-phase-iii-optimum-11-adjuvant-trial-of-darovasertib-plus-crizotinib-in-uveal-melanoma 2026-09-09T17:41:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-and-servier-dose-first-patient-in-phase-iii-optimum-11-adjuvant-trial-of-darovasertib-plus-crizotinib-in-uveal-melanoma 2026-09-09T17:41:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-alebund-s-first-in-class-iga-protease-ap308-in-iga-nephropathy 2026-09-09T17:41:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-alebund-s-first-in-class-iga-protease-ap308-in-iga-nephropathy 2026-09-09T17:41:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-full-life-s-actinium-225-c-met-radioconjugate-225ac-ac-fl-261-in-non-squamous-nsclc 2026-09-09T16:50:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-full-life-s-actinium-225-c-met-radioconjugate-225ac-ac-fl-261-in-non-squamous-nsclc 2026-09-09T16:50:07+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-awards-up-to-8-9m-to-pune-s-immunoscript-for-thermostable-sarna-vaccine-platform 2026-09-09T16:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepi-awards-up-to-8-9m-to-pune-s-immunoscript-for-thermostable-sarna-vaccine-platform 2026-09-09T16:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-hanchorbio-s-hcb101-single-patient-expanded-access-protocol-a-first-for-sirpa-fc-fusion-proteins 2026-09-09T16:02:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-hanchorbio-s-hcb101-single-patient-expanded-access-protocol-a-first-for-sirpa-fc-fusion-proteins 2026-09-09T16:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-bayer-s-hyrnuo-sevabertinib-as-first-line-therapy-for-her2-mutant-nsclc 2026-09-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-bayer-s-hyrnuo-sevabertinib-as-first-line-therapy-for-her2-mutant-nsclc 2026-09-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/waldenstrom-macroglobulinemia-market-poised-for-steady-growth-through-2036-on-novel-btk-degraders-non-covalent-btkis-and-targeted-radiotherapeutics 2026-09-09T15:50:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waldenstrom-macroglobulinemia-market-poised-for-steady-growth-through-2036-on-novel-btk-degraders-non-covalent-btkis-and-targeted-radiotherapeutics 2026-09-09T15:50:32+00:00 hourly 0.9 https://trial.medpath.com/news/adagene-achieves-milestone-in-exelixis-collaboration-for-safebody 2026-09-09T15:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adagene-achieves-milestone-in-exelixis-collaboration-for-safebody 2026-09-09T15:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/orderlymeds-and-veo-health-partner-to-pair-glp-1-therapies-with-biomarker-testing 2026-09-09T15:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orderlymeds-and-veo-health-partner-to-pair-glp-1-therapies-with-biomarker-testing 2026-09-09T15:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-co-founds-tectora-therapeutics-with-55m-series-a-to-advance-immunology-and-inflammation-programs 2026-09-09T15:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-co-founds-tectora-therapeutics-with-55m-series-a-to-advance-immunology-and-inflammation-programs 2026-09-09T15:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/brain-biotech-receives-eur-11-51-million-milestone-payment-from-royalty-pharma-for-deucrictibant 2026-09-09T15:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-biotech-receives-eur-11-51-million-milestone-payment-from-royalty-pharma-for-deucrictibant 2026-09-09T15:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/promis-neurosciences-reports-interim-phase-1b-data-for-pmn310-showing-strong-safety-and-biomarker-signals 2026-09-09T15:30:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promis-neurosciences-reports-interim-phase-1b-data-for-pmn310-showing-strong-safety-and-biomarker-signals 2026-09-09T15:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-del-desiran-misses-primary-endpoint-in-phase-3-harbor-rattling-dmpk-targeting-field 2026-09-09T15:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-del-desiran-misses-primary-endpoint-in-phase-3-harbor-rattling-dmpk-targeting-field 2026-09-09T15:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-s-emd-serono-acquires-postera-s-oral-fertility-programs-targeting-fshr-and-lhcgr 2026-09-09T14:51:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-s-emd-serono-acquires-postera-s-oral-fertility-programs-targeting-fshr-and-lhcgr 2026-09-09T14:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-acquires-mlm-medical-labs-creating-first-wholly-owned-central-lab-network-across-four-continents 2026-09-09T14:46:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-acquires-mlm-medical-labs-creating-first-wholly-owned-central-lab-network-across-four-continents 2026-09-09T14:46:41+00:00 hourly 0.9 https://trial.medpath.com/news/leyden-labs-advances-intranasal-rig-i-agonist-rig-101-to-rhinovirus-challenge-trial-after-phase-i-safety-and-biomarker-success 2026-09-09T14:40:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leyden-labs-advances-intranasal-rig-i-agonist-rig-101-to-rhinovirus-challenge-trial-after-phase-i-safety-and-biomarker-success 2026-09-09T14:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-opens-182000-sq-ft-foster-city-research-hub-under-32bn-us-investment-programme 2026-09-09T14:23:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-opens-182000-sq-ft-foster-city-research-hub-under-32bn-us-investment-programme 2026-09-09T14:23:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-intellia-s-lonvo-z-an-in-vivo-crispr-therapy-for-hereditary-angioedema 2026-09-09T14:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-intellia-s-lonvo-z-an-in-vivo-crispr-therapy-for-hereditary-angioedema 2026-09-09T14:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-s-oral-infigratinib-shows-benefits-beyond-growth-in-phase-3-propel-3-achondroplasia-trial 2026-09-09T14:18:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-s-oral-infigratinib-shows-benefits-beyond-growth-in-phase-3-propel-3-achondroplasia-trial 2026-09-09T14:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/why-promising-compounds-still-fail-drug-discovery-shifts-toward-earlier-translatability-testing 2026-09-09T13:49:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/why-promising-compounds-still-fail-drug-discovery-shifts-toward-earlier-translatability-testing 2026-09-09T13:49:56+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-to-acquire-human-cell-design-adding-human-pancreatic-beta-cell-models-for-metabolic-drug-discovery 2026-09-09T13:49:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revvity-to-acquire-human-cell-design-adding-human-pancreatic-beta-cell-models-for-metabolic-drug-discovery 2026-09-09T13:49:53+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-s-oral-mrgprx2-antagonist-evo756-fails-phase-2b-in-atopic-dermatitis-program-halted 2026-09-09T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evommune-s-oral-mrgprx2-antagonist-evo756-fails-phase-2b-in-atopic-dermatitis-program-halted 2026-09-09T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharvaris-s-oral-deucrictibant-xr-cuts-hae-attack-rate-83-in-phase-iii-chapter-3 2026-09-09T13:38:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharvaris-s-oral-deucrictibant-xr-cuts-hae-attack-rate-83-in-phase-iii-chapter-3 2026-09-09T13:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/lancet-publishes-phase-1-data-for-pepromene-s-baff-r-car-t-80-complete-response-grade-1-only-toxicity 2026-09-09T13:38:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lancet-publishes-phase-1-data-for-pepromene-s-baff-r-car-t-80-complete-response-grade-1-only-toxicity 2026-09-09T13:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/rentosertib-shifts-six-proteomic-aging-clocks-in-phase-2a-ipf-substudy-but-cannot-separate-anti-aging-from-anti-fibrotic-effects 2026-09-09T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rentosertib-shifts-six-proteomic-aging-clocks-in-phase-2a-ipf-substudy-but-cannot-separate-anti-aging-from-anti-fibrotic-effects 2026-09-09T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-comp360-holds-13-point-madrs-benefit-at-52-weeks-in-phase-3-comp005-nda-submission-set-for-q4 2026-09-09T13:21:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-pathways-comp360-holds-13-point-madrs-benefit-at-52-weeks-in-phase-3-comp005-nda-submission-set-for-q4 2026-09-09T13:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/opus-genetics-reports-positive-low-dose-cohort-1-data-for-opgx-best1-in-best1-related-retinal-diseases-aligns-with-fda-on-pivotal-endpoint 2026-09-09T13:18:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opus-genetics-reports-positive-low-dose-cohort-1-data-for-opgx-best1-in-best1-related-retinal-diseases-aligns-with-fda-on-pivotal-endpoint 2026-09-09T13:18:15+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-voxzogo-hits-primary-endpoint-in-phase-3-hypochondroplasia-trial-published-in-nejm-evidence 2026-09-09T13:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-s-voxzogo-hits-primary-endpoint-in-phase-3-hypochondroplasia-trial-published-in-nejm-evidence 2026-09-09T13:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-s-ersodetug-phase-3-sunrize-misses-primary-endpoint-in-congenital-hyperinsulinism-fda-review-continues 2026-09-09T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezolute-s-ersodetug-phase-3-sunrize-misses-primary-endpoint-in-congenital-hyperinsulinism-fda-review-continues 2026-09-09T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/nejm-publishes-phase-3-data-for-takeda-s-oveporexton-the-first-approved-orexin-agonist-for-narcolepsy-type-1 2026-09-09T12:27:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nejm-publishes-phase-3-data-for-takeda-s-oveporexton-the-first-approved-orexin-agonist-for-narcolepsy-type-1 2026-09-09T12:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/solstice-oncology-launches-with-225m-series-a-to-advance-next-generation-ctla-4-antibody-porustobart-in-neoadjuvant-colon-cancer 2026-09-09T12:20:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solstice-oncology-launches-with-225m-series-a-to-advance-next-generation-ctla-4-antibody-porustobart-in-neoadjuvant-colon-cancer 2026-09-09T12:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-spins-out-caspian-therapeutics-with-50m-to-develop-menin-inhibitors-for-diabetes 2026-09-09T12:19:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-spins-out-caspian-therapeutics-with-50m-to-develop-menin-inhibitors-for-diabetes 2026-09-09T12:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/bms-gprc5d-car-t-arlo-cel-hits-primary-endpoint-in-quadruple-class-exposed-multiple-myeloma 2026-09-09T12:18:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-gprc5d-car-t-arlo-cel-hits-primary-endpoint-in-quadruple-class-exposed-multiple-myeloma 2026-09-09T12:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-doses-first-participant-in-phase-1-study-of-ax-0811 2026-09-09T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proqr-doses-first-participant-in-phase-1-study-of-ax-0811 2026-09-09T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-launches-global-phase-ii-trial-of-girk4-inhibitor-bay-3670549-in-atrial-fibrillation 2026-09-09T11:42:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-launches-global-phase-ii-trial-of-girk4-inhibitor-bay-3670549-in-atrial-fibrillation 2026-09-09T11:42:41+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsygtx-taps-viralgen-s-aava-platform-to-manufacture-aav-gene-therapy-epy201-ahead-of-first-in-human-trial 2026-09-09T11:26:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epilepsygtx-taps-viralgen-s-aava-platform-to-manufacture-aav-gene-therapy-epy201-ahead-of-first-in-human-trial 2026-09-09T11:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-camizestrant-for-esr1-mutant-hr-positive-her2-negative-breast-cancer-four-months-after-advisers-voted-no 2026-09-09T11:21:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-camizestrant-for-esr1-mutant-hr-positive-her2-negative-breast-cancer-four-months-after-advisers-voted-no 2026-09-09T11:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/pyxis-oncology-s-micvo-posts-36-confirmed-orr-and-79-12-month-os-probability-in-2l-r-m-head-and-neck-cancer 2026-09-09T11:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyxis-oncology-s-micvo-posts-36-confirmed-orr-and-79-12-month-os-probability-in-2l-r-m-head-and-neck-cancer 2026-09-09T11:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-nanoscope-s-bla-for-mogenry-an-optogenetic-gene-therapy-for-severe-vision-loss-in-retinitis-pigmentosa 2026-09-09T11:12:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-nanoscope-s-bla-for-mogenry-an-optogenetic-gene-therapy-for-severe-vision-loss-in-retinitis-pigmentosa 2026-09-09T11:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/tozorakimab-cuts-copd-exacerbations-by-up-to-34-in-two-phase-3-trials-fda-sets-q1-2027-decision 2026-09-09T11:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tozorakimab-cuts-copd-exacerbations-by-up-to-34-in-two-phase-3-trials-fda-sets-q1-2027-decision 2026-09-09T11:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-therapeutics-completes-enrollment-in-phase-1-2-start-001-monotherapy-cohorts-for-invikafusp-alfa-in-pd-1-resistant-solid-tumors 2026-09-09T11:02:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-therapeutics-completes-enrollment-in-phase-1-2-start-001-monotherapy-cohorts-for-invikafusp-alfa-in-pd-1-resistant-solid-tumors 2026-09-09T11:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/tyra-s-oral-fgfr3-inhibitor-dabogratinib-hits-100-orr-in-single-lesion-nmibc-but-phase-2-data-miss-street-bar 2026-09-09T11:01:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyra-s-oral-fgfr3-inhibitor-dabogratinib-hits-100-orr-in-single-lesion-nmibc-but-phase-2-data-miss-street-bar 2026-09-09T11:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-cimzia-for-preventing-adverse-pregnancy-outcomes-in-antiphospholipid-syndrome 2026-09-09T09:49:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-cimzia-for-preventing-adverse-pregnancy-outcomes-in-antiphospholipid-syndrome 2026-09-09T09:49:06+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-doses-first-patient-in-phase-2-sjogren-s-trial-of-vav1-degrader-mrt-6160-triggering-50m-payment-to-monte-rosa 2026-09-09T09:48:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-doses-first-patient-in-phase-2-sjogren-s-trial-of-vav1-degrader-mrt-6160-triggering-50m-payment-to-monte-rosa 2026-09-09T09:48:50+00:00 hourly 0.9 https://trial.medpath.com/news/jst-018-orthopoxvirus-antibody-cocktail-advances-into-first-in-human-phase-1-trial-under-u-s-department-of-war-program 2026-09-09T08:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jst-018-orthopoxvirus-antibody-cocktail-advances-into-first-in-human-phase-1-trial-under-u-s-department-of-war-program 2026-09-09T08:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/redasemtide-clears-ulcer-endpoint-in-dystrophic-eb-but-misses-primary-endpoint-in-global-phase-2-acute-ischemic-stroke-trial 2026-09-09T07:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redasemtide-clears-ulcer-endpoint-in-dystrophic-eb-but-misses-primary-endpoint-in-global-phase-2-acute-ischemic-stroke-trial 2026-09-09T07:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/western-australia-awards-775000-to-15-precision-medicine-projects-spanning-cancer-alzheimer-s-and-stroke 2026-09-09T06:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/western-australia-awards-775000-to-15-precision-medicine-projects-spanning-cancer-alzheimer-s-and-stroke 2026-09-09T06:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/rcp-review-finds-betrayal-of-trust-in-prolonged-temozolomide-prescribing-at-coventry-nhs-trust 2026-09-09T06:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rcp-review-finds-betrayal-of-trust-in-prolonged-temozolomide-prescribing-at-coventry-nhs-trust 2026-09-09T06:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/brandi-glanville-details-multidrug-resistant-infection-and-fungal-ball-diagnosis-ahead-of-surgery 2026-09-09T06:49:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brandi-glanville-details-multidrug-resistant-infection-and-fungal-ball-diagnosis-ahead-of-surgery 2026-09-09T06:49:23+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-riken-and-ibm-named-finalists-for-2026-acm-gordon-bell-prize-for-quantum-simulation-of-a-12635-atom-protein 2026-09-09T05:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-riken-and-ibm-named-finalists-for-2026-acm-gordon-bell-prize-for-quantum-simulation-of-a-12635-atom-protein 2026-09-09T05:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/forus-raises-150m-series-c-at-3b-valuation-to-scale-ai-network-for-medicine-access 2026-09-09T04:50:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forus-raises-150m-series-c-at-3b-valuation-to-scale-ai-network-for-medicine-access 2026-09-09T04:50:43+00:00 hourly 0.9 https://trial.medpath.com/news/hae-care-shifts-toward-attack-free-goals-as-experts-outline-when-to-reassess-treatment 2026-09-09T04:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hae-care-shifts-toward-attack-free-goals-as-experts-outline-when-to-reassess-treatment 2026-09-09T04:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fills-four-senior-leadership-roles-naming-permanent-directors-for-drugs-vaccines-and-tobacco 2026-09-09T03:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fills-four-senior-leadership-roles-naming-permanent-directors-for-drugs-vaccines-and-tobacco 2026-09-09T03:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/systematic-review-finds-very-low-certainty-evidence-for-hospital-based-interventions-linking-aud-patients-to-outpatient-care 2026-09-09T02:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systematic-review-finds-very-low-certainty-evidence-for-hospital-based-interventions-linking-aud-patients-to-outpatient-care 2026-09-09T02:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/inhibitor-therapeutics-advances-itraconazole-for-gorlin-syndrome-reports-0-265-new-surgically-eligible-bccs-per-patient-year 2026-09-08T23:52:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibitor-therapeutics-advances-itraconazole-for-gorlin-syndrome-reports-0-265-new-surgically-eligible-bccs-per-patient-year 2026-09-08T23:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/rbqm-delivers-six-to-23-fold-return-on-investment-as-trial-complexity-becomes-the-new-normal 2026-09-08T23:52:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rbqm-delivers-six-to-23-fold-return-on-investment-as-trial-complexity-becomes-the-new-normal 2026-09-08T23:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/horien-wins-three-thai-fda-class-4-approvals-for-regenerative-devices-and-u-s-patent-for-biodegradable-ureteral-stent 2026-09-08T23:52:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/horien-wins-three-thai-fda-class-4-approvals-for-regenerative-devices-and-u-s-patent-for-biodegradable-ureteral-stent 2026-09-08T23:52:13+00:00 hourly 0.9 https://trial.medpath.com/news/texas-couple-sentenced-for-smuggling-unapproved-veterinary-drugs-and-pesticides-into-the-u-s 2026-09-08T22:56:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-couple-sentenced-for-smuggling-unapproved-veterinary-drugs-and-pesticides-into-the-u-s 2026-09-08T22:56:50+00:00 hourly 0.9 https://trial.medpath.com/news/family-calls-for-nhs-england-access-to-enhertu-after-woman-dies-of-breast-cancer-at-32 2026-09-08T18:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/family-calls-for-nhs-england-access-to-enhertu-after-woman-dies-of-breast-cancer-at-32 2026-09-08T18:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-ty1-reverses-systemic-sclerosis-effects-in-preclinical-study 2026-09-08T17:49:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-drug-ty1-reverses-systemic-sclerosis-effects-in-preclinical-study 2026-09-08T17:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/eppendorf-launches-refrigerated-centrifuge-5811-r-with-sustainable-r290-cooling 2026-09-08T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eppendorf-launches-refrigerated-centrifuge-5811-r-with-sustainable-r290-cooling 2026-09-08T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/west-virginia-reports-12-drop-in-drug-overdose-deaths-alongside-declines-in-violent-and-property-crime 2026-09-08T16:51:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/west-virginia-reports-12-drop-in-drug-overdose-deaths-alongside-declines-in-violent-and-property-crime 2026-09-08T16:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/scibase-receives-additional-order-from-castle-biosciences-to-accelerate-atopic-dermatitis-relapse-prediction-studies 2026-09-08T16:50:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scibase-receives-additional-order-from-castle-biosciences-to-accelerate-atopic-dermatitis-relapse-prediction-studies 2026-09-08T16:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/global-genes-partners-with-citizen-health-to-power-rare-x-rare-disease-data-platform 2026-09-08T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-genes-partners-with-citizen-health-to-power-rare-x-rare-disease-data-platform 2026-09-08T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-signs-exclusive-distribution-deal-with-akron-biotech-for-car-t-manufacturing-reagent-hcw11-006 2026-09-08T16:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-signs-exclusive-distribution-deal-with-akron-biotech-for-car-t-manufacturing-reagent-hcw11-006 2026-09-08T16:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/duane-a-mitchell-named-director-of-the-uf-health-cancer-institute 2026-09-08T15:50:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duane-a-mitchell-named-director-of-the-uf-health-cancer-institute 2026-09-08T15:50:24+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-ct-analysis-detects-significant-taladegib-treatment-effects-in-phase-2a-ipf-trial 2026-09-08T15:50:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-ct-analysis-detects-significant-taladegib-treatment-effects-in-phase-2a-ipf-trial 2026-09-08T15:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/me-therapeutics-advances-in-vivo-cd19-cd22-car-and-liver-detargeted-sting-mrna-programs 2026-09-08T15:49:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/me-therapeutics-advances-in-vivo-cd19-cd22-car-and-liver-detargeted-sting-mrna-programs 2026-09-08T15:49:59+00:00 hourly 0.9 https://trial.medpath.com/news/imdelltra-plus-imfinzi-delivers-landmark-overall-survival-benefit-in-first-line-extensive-stage-small-cell-lung-cancer 2026-09-08T14:51:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imdelltra-plus-imfinzi-delivers-landmark-overall-survival-benefit-in-first-line-extensive-stage-small-cell-lung-cancer 2026-09-08T14:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-acquires-mlm-medical-labs-becoming-the-only-central-lab-provider-with-a-wholly-owned-network-across-four-continents 2026-09-08T14:50:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-acquires-mlm-medical-labs-becoming-the-only-central-lab-provider-with-a-wholly-owned-network-across-four-continents 2026-09-08T14:50:52+00:00 hourly 0.9 https://trial.medpath.com/news/vapendavir-significantly-reduces-key-inflammatory-biomarkers-in-rhinovirus-challenged-copd-patients 2026-09-08T14:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vapendavir-significantly-reduces-key-inflammatory-biomarkers-in-rhinovirus-challenged-copd-patients 2026-09-08T14:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/orphalan-initiates-global-phase-3-traditional-study-of-once-daily-trientine-in-wilson-disease 2026-09-08T14:50:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orphalan-initiates-global-phase-3-traditional-study-of-once-daily-trientine-in-wilson-disease 2026-09-08T14:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/maxwell-biosciences-mxb-22510-sc-receives-fda-qidp-designation-for-bacterial-and-fungal-pneumonia 2026-09-08T14:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxwell-biosciences-mxb-22510-sc-receives-fda-qidp-designation-for-bacterial-and-fungal-pneumonia 2026-09-08T14:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/scinai-ends-pc111-deal-redirects-capital-to-nanoab-platform-and-cdmo-growth 2026-09-08T14:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scinai-ends-pc111-deal-redirects-capital-to-nanoab-platform-and-cdmo-growth 2026-09-08T14:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/veru-advances-oral-sabizabulin-after-preclinical-data-show-potent-activity-in-daraxonrasib-resistant-pancreatic-cancer 2026-09-08T13:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veru-advances-oral-sabizabulin-after-preclinical-data-show-potent-activity-in-daraxonrasib-resistant-pancreatic-cancer 2026-09-08T13:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/moonwalk-biosciences-closes-70m-series-b-to-advance-adipose-targeted-rnai-for-obesity 2026-09-08T13:50:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonwalk-biosciences-closes-70m-series-b-to-advance-adipose-targeted-rnai-for-obesity 2026-09-08T13:50:48+00:00 hourly 0.9 https://trial.medpath.com/news/accro-bioscience-announces-nmpa-clearance-for-phase-ii-iii-trial-of-ac-201-a-selective-tyk2-jak1-inhibitor-for-non-segmental-vitiligo 2026-09-08T13:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accro-bioscience-announces-nmpa-clearance-for-phase-ii-iii-trial-of-ac-201-a-selective-tyk2-jak1-inhibitor-for-non-segmental-vitiligo 2026-09-08T13:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/cloverleaf-bio-raises-33-million-seed-financing-to-advance-engineered-trna-cancer-therapeutics 2026-09-08T12:51:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cloverleaf-bio-raises-33-million-seed-financing-to-advance-engineered-trna-cancer-therapeutics 2026-09-08T12:51:33+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-reconsiders-coverage-of-dcisionrt-raising-stakes-for-precision-medicine-diagnostics 2026-09-08T12:51:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-reconsiders-coverage-of-dcisionrt-raising-stakes-for-precision-medicine-diagnostics 2026-09-08T12:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/welltrust-surpasses-100000-patient-consents-paving-the-way-for-ai-driven-clinical-trial-recruitment 2026-09-08T12:50:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/welltrust-surpasses-100000-patient-consents-paving-the-way-for-ai-driven-clinical-trial-recruitment 2026-09-08T12:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-to-present-phase-3-caplyta-data-across-bipolar-mania-depression-and-schizophrenia-at-psych-congress-2026 2026-09-08T12:50:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-to-present-phase-3-caplyta-data-across-bipolar-mania-depression-and-schizophrenia-at-psych-congress-2026 2026-09-08T12:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-appoints-keith-j-lane-as-evp-of-global-clinical-development-and-regulatory-affairs 2026-09-08T12:49:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-appoints-keith-j-lane-as-evp-of-global-clinical-development-and-regulatory-affairs 2026-09-08T12:49:38+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-publishes-preclinical-data-showing-complementary-immunomodulatory-effects-of-coya-303-in-neuroinflammation-model 2026-09-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-publishes-preclinical-data-showing-complementary-immunomodulatory-effects-of-coya-303-in-neuroinflammation-model 2026-09-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pepromene-bio-s-baff-r-car-t-cell-therapy-shows-80-complete-response-rate-in-relapsed-refractory-b-cell-lymphomas 2026-09-08T11:49:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepromene-bio-s-baff-r-car-t-cell-therapy-shows-80-complete-response-rate-in-relapsed-refractory-b-cell-lymphomas 2026-09-08T11:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/egypt-s-eda-wins-who-prequalification-for-drug-quality-control-labs-cementing-maturity-level-3-status 2026-09-08T11:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egypt-s-eda-wins-who-prequalification-for-drug-quality-control-labs-cementing-maturity-level-3-status 2026-09-08T11:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/quality-over-quantity-specific-car-t-cell-subgroup-may-predict-low-dose-therapy-success 2026-09-08T11:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quality-over-quantity-specific-car-t-cell-subgroup-may-predict-low-dose-therapy-success 2026-09-08T11:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-shares-plunge-as-del-desiran-misses-primary-endpoint-in-myotonic-dystrophy-trial 2026-09-08T10:51:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-shares-plunge-as-del-desiran-misses-primary-endpoint-in-myotonic-dystrophy-trial 2026-09-08T10:51:01+00:00 hourly 0.9 https://trial.medpath.com/news/allergic-rhinoconjunctivitis-market-set-for-evolution-through-2036-as-immunotherapy-access-expands 2026-09-08T09:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergic-rhinoconjunctivitis-market-set-for-evolution-through-2036-as-immunotherapy-access-expands 2026-09-08T09:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-nitinol-super-elastic-springs-reshape-baby-s-skull-in-craniosynostosis-surgery 2026-09-08T08:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-nitinol-super-elastic-springs-reshape-baby-s-skull-in-craniosynostosis-surgery 2026-09-08T08:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/multi-site-validation-study-confirms-diagnostic-grade-ai-biomarker-detection-from-routine-brightfield-images 2026-09-08T08:50:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-site-validation-study-confirms-diagnostic-grade-ai-biomarker-detection-from-routine-brightfield-images 2026-09-08T08:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/panntherapi-receives-ansm-approval-to-advance-first-in-class-panx1-targeting-therapy-pti5803-into-phase-2a-in-focal-cortical-dysplasia 2026-09-08T08:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panntherapi-receives-ansm-approval-to-advance-first-in-class-panx1-targeting-therapy-pti5803-into-phase-2a-in-focal-cortical-dysplasia 2026-09-08T08:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/transgene-and-probiogen-expand-strategic-partnership-with-additional-license-for-age1-cr-pix-cell-line 2026-09-08T07:50:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transgene-and-probiogen-expand-strategic-partnership-with-additional-license-for-age1-cr-pix-cell-line 2026-09-08T07:50:52+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-map-the-enzymatic-route-that-builds-5-azacytidine-in-nature-revealing-a-rare-skeletal-editing-reaction 2026-09-08T07:50:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-map-the-enzymatic-route-that-builds-5-azacytidine-in-nature-revealing-a-rare-skeletal-editing-reaction 2026-09-08T07:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-advances-gs010-lumevoq-manufacturing-transfer-and-early-access-programs 2026-09-08T07:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-biologics-advances-gs010-lumevoq-manufacturing-transfer-and-early-access-programs 2026-09-08T07:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/deconstructing-lsd-s-ergoline-core-yields-simplified-compounds-with-reduced-hallucinogenic-and-cardiotoxic-effects 2026-09-08T04:49:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deconstructing-lsd-s-ergoline-core-yields-simplified-compounds-with-reduced-hallucinogenic-and-cardiotoxic-effects 2026-09-08T04:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-secures-10-year-brazil-supply-contract-for-pertuzumab-in-her2-positive-breast-cancer 2026-09-08T04:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-secures-10-year-brazil-supply-contract-for-pertuzumab-in-her2-positive-breast-cancer 2026-09-08T04:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/arm-holdings-ceo-ai-will-help-find-a-cure-for-cancer-within-our-lifetimes 2026-09-08T03:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arm-holdings-ceo-ai-will-help-find-a-cure-for-cancer-within-our-lifetimes 2026-09-08T03:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/tbe-base-editing-therapy-achieves-durable-remission-in-sickle-cell-disease-and-b-thalassemia-across-diverse-genetic-backgrounds 2026-09-08T01:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tbe-base-editing-therapy-achieves-durable-remission-in-sickle-cell-disease-and-b-thalassemia-across-diverse-genetic-backgrounds 2026-09-08T01:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/uk-pharma-investment-shows-green-shoots-with-ps2bn-committed-but-delivery-will-decide-recovery 2026-09-08T00:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-pharma-investment-shows-green-shoots-with-ps2bn-committed-but-delivery-will-decide-recovery 2026-09-08T00:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/convicted-murderer-erin-patterson-approved-for-taxpayer-funded-ozempic-in-victorian-prison 2026-09-08T00:52:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/convicted-murderer-erin-patterson-approved-for-taxpayer-funded-ozempic-in-victorian-prison 2026-09-08T00:52:04+00:00 hourly 0.9 https://trial.medpath.com/news/personalised-risk-adapted-therapy-doubles-six-year-survival-in-high-risk-multiple-myeloma 2026-09-08T00:50:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalised-risk-adapted-therapy-doubles-six-year-survival-in-high-risk-multiple-myeloma 2026-09-08T00:50:49+00:00 hourly 0.9 https://trial.medpath.com/news/prolight-signs-usd-3-9-million-supply-agreement-with-brainbox-for-tbi-point-of-care-diagnostics 2026-09-08T00:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prolight-signs-usd-3-9-million-supply-agreement-with-brainbox-for-tbi-point-of-care-diagnostics 2026-09-08T00:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/community-acquired-bacterial-pneumonia-market-poised-for-expansion-through-2036-amid-rising-antimicrobial-resistance 2026-09-07T19:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-acquired-bacterial-pneumonia-market-poised-for-expansion-through-2036-amid-rising-antimicrobial-resistance 2026-09-07T19:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/osf-cancer-institute-joins-hoosier-cancer-research-network-to-expand-trial-access-in-central-illinois 2026-09-07T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osf-cancer-institute-joins-hoosier-cancer-research-network-to-expand-trial-access-in-central-illinois 2026-09-07T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-cancer-drug-cadd522-shows-promise-against-osteoporosis-and-menopause-related-weight-gain 2026-09-07T17:50:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-cancer-drug-cadd522-shows-promise-against-osteoporosis-and-menopause-related-weight-gain 2026-09-07T17:50:58+00:00 hourly 0.9 https://trial.medpath.com/news/vascular-origins-of-alzheimer-s-disease-gain-ground-as-amyloid-hypothesis-faces-mounting-challenges 2026-09-07T17:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vascular-origins-of-alzheimer-s-disease-gain-ground-as-amyloid-hypothesis-faces-mounting-challenges 2026-09-07T17:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/erc-starting-grant-funds-in-vivo-car-t-cell-therapy-using-lipid-nanoparticles-and-genome-editing 2026-09-07T17:49:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erc-starting-grant-funds-in-vivo-car-t-cell-therapy-using-lipid-nanoparticles-and-genome-editing 2026-09-07T17:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-supreme-court-rejects-pil-challenging-national-hpv-vaccination-programme 2026-09-07T17:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-supreme-court-rejects-pil-challenging-national-hpv-vaccination-programme 2026-09-07T17:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-and-aceso-therapeutics-partner-to-advance-inhaled-antisense-oligonucleotide-therapy-for-cystic-fibrosis 2026-09-07T16:49:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-and-aceso-therapeutics-partner-to-advance-inhaled-antisense-oligonucleotide-therapy-for-cystic-fibrosis 2026-09-07T16:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/new-initiative-seeks-500m-to-commercialize-israeli-life-science 2026-09-07T16:49:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-initiative-seeks-500m-to-commercialize-israeli-life-science 2026-09-07T16:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/drug-reconstitution-systems-market-poised-for-growth-through-2035-as-injectable-delivery-advances 2026-09-07T14:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-reconstitution-systems-market-poised-for-growth-through-2035-as-injectable-delivery-advances 2026-09-07T14:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/senate-to-hold-first-ever-congressional-hearing-on-menopause-as-women-s-health-research-funding-lags 2026-09-07T13:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-to-hold-first-ever-congressional-hearing-on-menopause-as-women-s-health-research-funding-lags 2026-09-07T13:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/king-s-college-hospital-recruits-world-s-first-patient-in-phase-3-trial-of-erlitercept-for-lower-risk-mds 2026-09-07T12:48:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/king-s-college-hospital-recruits-world-s-first-patient-in-phase-3-trial-of-erlitercept-for-lower-risk-mds 2026-09-07T12:48:57+00:00 hourly 0.9 https://trial.medpath.com/news/ibd-s-persistent-unmet-need-durable-remission-and-mucosal-healing-remain-the-missing-piece 2026-09-07T11:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibd-s-persistent-unmet-need-durable-remission-and-mucosal-healing-remain-the-missing-piece 2026-09-07T11:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/bi-multispecific-drugs-surge-in-oncology-278-new-candidates-added-in-2024-25 2026-09-07T10:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bi-multispecific-drugs-surge-in-oncology-278-new-candidates-added-in-2024-25 2026-09-07T10:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-india-to-acquire-pfizer-s-minipress-trademark-for-1250-crore 2026-09-07T10:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-india-to-acquire-pfizer-s-minipress-trademark-for-1250-crore 2026-09-07T10:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-nemolizumab-research-honored-with-11th-jbda-award-for-drug-discovery 2026-09-07T09:49:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-s-nemolizumab-research-honored-with-11th-jbda-award-for-drug-discovery 2026-09-07T09:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/liverpool-launches-uk-first-ps20m-high-security-robotic-ai-lab-to-accelerate-drug-and-vaccine-discovery 2026-09-07T09:49:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liverpool-launches-uk-first-ps20m-high-security-robotic-ai-lab-to-accelerate-drug-and-vaccine-discovery 2026-09-07T09:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/sudarshan-pharma-to-acquire-9-5-stake-in-car-t-cell-cdmo-medtherapy-biotechnology 2026-09-07T08:49:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sudarshan-pharma-to-acquire-9-5-stake-in-car-t-cell-cdmo-medtherapy-biotechnology 2026-09-07T08:49:15+00:00 hourly 0.9 https://trial.medpath.com/news/bone-marrow-transplant-saves-alabama-boy-with-rare-wiskott-aldrich-syndrome 2026-09-07T08:49:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bone-marrow-transplant-saves-alabama-boy-with-rare-wiskott-aldrich-syndrome 2026-09-07T08:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/rznomics-reports-major-advances-in-high-efficiency-circular-rna-production 2026-09-07T08:49:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rznomics-reports-major-advances-in-high-efficiency-circular-rna-production 2026-09-07T08:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/louisiana-family-rallies-support-for-foxp1-syndrome-gene-therapy-research 2026-09-07T08:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/louisiana-family-rallies-support-for-foxp1-syndrome-gene-therapy-research 2026-09-07T08:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/nature-reviews-drug-discovery-review-positions-slc-transporters-as-untapped-frontier-in-cns-drug-development 2026-09-07T08:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-reviews-drug-discovery-review-positions-slc-transporters-as-untapped-frontier-in-cns-drug-development 2026-09-07T08:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/ondine-biomedical-partners-with-mexico-s-largest-private-hospital-network-to-pilot-steriwave-nasal-photodisinfection 2026-09-07T08:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ondine-biomedical-partners-with-mexico-s-largest-private-hospital-network-to-pilot-steriwave-nasal-photodisinfection 2026-09-07T08:06:05+00:00 hourly 0.9